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ABSTRACT 
Prostaglandin E2 (PGE2) is an endogenous lipid-derived signalling molecule, synthesized 
in part by the rate-limiting enzymes Cyclooxygenase-1 and 2 (COX-1 and 2). Along with 
inducing inflammation, PGE2 is important for brain development, neuronal transmission, 
plasticity and modulation of an important developmental pathway known as the Wnt pathway. 
Due to its role in brain development, any genetic or environmental factors interfering with PGE2 
levels may result in abnormal brain development and Autism Spectrum Disorders (ASDs). To 
explore the role of PGE2 in the developing brain we examine changes in the expression of genes 
and their associated pathways using RNA microarray analysis of mice brains lacking PGE2 
producing enzymes COX-1 and 2 at embryonic days 16 and 19. We also aim to determine 
whether there is an interaction between PGE2 and Wnt pathways in the brain of COX
-/- mice by 
western blot analysis of β-catenin, a key signal transducer in the Wnt pathway. We also aim to 
quantify the expression of selected developmental and ASD candidate genes in our cellular 
models exposed to a higher level of PGE2. Overall, we found a greater number of differentially 
expressed genes, of which more were down-regulation than up-regulation, in the E16 COX-/- 
mice than E19 mice. In addition, several important developmental and ASD candidate genes 
along with their corresponding neuronal pathways, including synaptic transmission and Wnt 
signalling pathways, were affected, particularly in the E16 COX-2-/- mice. We also found greater 
Protein Kinase A (PKA) induced β-catenin activation in the COX-2-/- E16 mice. PGE2 exposed 
neuroectodermal (NE-4C) stem cells and neuronal cells indicated changes in the expression of 
genes that were also differentially expressed in COX-/- microarray results. This research provides 
an in-depth look at the role of COX/PGE2 during prenatal brain development and the 
implications for the COX-/- mouse to serve a potential ASD model system.   
iii 
 
ACKNOWLEDGMENTS 
Having an opportunity to contribute to Autism research at the Neurodevelopmental Lab 
at York University has been an engaging and stimulating experience owing to the great people 
whom I have had the pleasure of working with. I would like to thank Dr. Dorota Crawford for 
allowing me to engage my scientific curiosity and providing vital guidance throughout this M.Sc 
degree; Dr. Emanuel Rosonina, for serving as Advisor and providing important feedback; Dr. 
Tara Haas, for serving as external examiner; Dr. Amro Zayed, for serving as deans 
representative; and Dr. Hongyan Li who provided me with valuable guidance and training on the 
bench.       
I owe much of the joy I have experienced during research to the incredibly bright lab-
mates that worked alongside me during my M.Sc., I would like to thank Ashby Kissoondoyal, 
Christine Wong, Denis Adigamov, Jennilee Davidson and Ravneet Bhogal who not only were 
always ready to help but also extended their friendship. Last but not the least, I would like to 
thank friends and family for their support; my parents for their hard work, unconditional support 
and encouragement; my brother, Muaaz, who is not only a friend but also a source of inspiration; 
and my sisters, Maryam and Maahum, for their support and encouragement.  
  
iv 
 
TABLE OF CONTENTS 
ABSTRACT ................................................................................................................................................. ii 
ACKNOWLEDGMENTS ......................................................................................................................... iii 
TABLE OF CONTENTS .......................................................................................................................... iv 
LIST OF TABLES ..................................................................................................................................... vi 
LIST OF FIGURES .................................................................................................................................. vii 
ABBREVIATIONS .................................................................................................................................. viii 
1.0. INTRODUCTION ................................................................................................................................ 1 
1.1. Autism Spectrum Disorders ............................................................................................................... 1 
1.2. ASD etiologies ................................................................................................................................... 3 
1.3. Environmental insults during brain development .............................................................................. 6 
1.4. The role of lipids in brain development ............................................................................................. 7 
1.5. The COX/PGE2 pathway ................................................................................................................... 9 
1.6. The PGE2 pathway in ASDs ............................................................................................................ 13 
1.7. The Wnt pathway ............................................................................................................................. 14 
1.8. Interaction between PGE2 and Wnt pathways ................................................................................. 16 
1.9. Objectives ........................................................................................................................................ 19 
1.10. Hypothesis...................................................................................................................................... 20 
Study 1: Microarray analysis in COX-/- mice models at E16 and E19 ................................................ 20 
Study 2: Gene expression of selected genes in PGE2 treated cell cultures ......................................... 20 
1.11. Experimental Model Systems ........................................................................................................ 20 
2.0. MATERIALS AND METHODS ...................................................................................................... 23 
2.1. Animals ............................................................................................................................................ 23 
2.2. Genotyping ....................................................................................................................................... 23 
2.3. Microarray........................................................................................................................................ 25 
2.4. Bioinformatics .................................................................................................................................. 25 
2.5. Cell cultures ..................................................................................................................................... 27 
2.6. RNA and protein isolation ............................................................................................................... 28 
2.7. Reverse transcription and PCR ........................................................................................................ 28 
2.8. Quantitative real-time PCR .............................................................................................................. 29 
2.9. Western blot analysis ....................................................................................................................... 32 
2.10. Statistics ......................................................................................................................................... 32 
3.0. RESULTS ........................................................................................................................................... 33 
v 
 
3.1. Study 1 ............................................................................................................................................. 33 
3.1.1. Differential gene expression impact and Venn diagram analysis in COX-1-/- or COX-2-/- mice 
models ................................................................................................................................................. 33 
3.1.2. Functional pathway analysis ..................................................................................................... 37 
3.1.3. ASD risk genes in COX-/- mice ................................................................................................. 43 
3.1.4. Cross-talk between COX-PGE2 and Wnt signalling pathways ................................................. 48 
3.1.6. Validation of gene expression ................................................................................................... 50 
3.1.5. Differential regulation of active forms of β-catenin in COX-/- mice ......................................... 50 
3.2. Study 2 ............................................................................................................................................. 54 
3.2.1. Gene expression in undifferentiated NE-4C stem cells ............................................................ 54 
3.2.2. Gene expression in neuronally differentiated NE-4C stem cells .............................................. 56 
4.0. DISCUSSION ..................................................................................................................................... 58 
4.1. Study 1 ............................................................................................................................................. 58 
4.1.1. Syndromic ASD genes .............................................................................................................. 60 
4.1.2. Synaptic development and transmission ................................................................................... 61 
4.1.3. COX-PGE2 and Wnt signalling ................................................................................................. 65 
4.1.4. Altered β-catenin activation in COX-/- mice ............................................................................. 67 
4.1.5. Limitations and future studies ................................................................................................... 70 
4.1.6. Conclusion ................................................................................................................................ 70 
4.2. Study 2 ............................................................................................................................................. 71 
4.2.1. Differential gene expression of key synaptic and developmental genes in differentiated and 
undifferentiated NE-4C stem cells ...................................................................................................... 71 
4.2.2. Differential gene expression in neuronally differentiated NE-4C stem cells ............................ 73 
4.2.3. Limitations and future studies ................................................................................................... 73 
4.2.4. Conclusion ................................................................................................................................ 74 
5.0. CONCLUSION .................................................................................................................................. 75 
6.0. REFERENCES ................................................................................................................................... 76 
7.0. APPENDIX ......................................................................................................................................... 91 
A.1. Supplementary Figure ..................................................................................................................... 91 
 
  
vi 
 
LIST OF TABLES 
Table 1: Primers designed for genotyping using PCR. ................................................................ 24 
Table 2: Primers designed for qRT-PCR. .................................................................................... 31 
Table 3: Enriched GO:BP and KEGG pathways affected in the COX-1-/- and COX-2-/- mice at 
E16. ............................................................................................................................................... 40 
Table 4: Enriched GO:BP and KEGG pathways affected in the COX-1-/- and COX-2-/- mice at 
E19. ............................................................................................................................................... 42 
Table 5: ASD associated genes differentially expressed in (A) COX-1-/- E16, (B) COX-2-/- E16, 
(C) COX-1-/- E19 and (D) COX-2-/- E19. ..................................................................................... 44 
Table S1: FC of all genes differentially expressed in COX-1-/- E16, COX-2-/- E16, COX-1-/- E19, 
and COX-2-/- E16. ......................................................................................................................... 91 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vii 
 
LIST OF FIGURES 
Figure 1: An overview of the prostanoid synthesis pathway and environmental interactions. ... 12 
Figure 2: A simplified overview of the Wnt/β-catenin (canonical) pathway. ............................. 18 
Figure 3: An overview of differentially expressed genes in COX-1-/- or COX-2-/- at E16 and E19.
....................................................................................................................................................... 35 
Figure 4: Comparison of the number of genes differentially expressed between the COX-/- 
animals of stage E16 and E19. ...................................................................................................... 36 
Figure 5: The interaction between Wnt and PGE2 pathways with genes found in the COX-2
-/- 
mice at E16. .................................................................................................................................. 49 
Figure 6: Levels of phospho β-catenin (S552) and non-phospho β-catenin (S33/S37/T41) in both 
COX-1-/- and 2-/- mice models, compared to WT, at the E16 stage. ............................................. 52 
Figure 7: Levels of phospho β-catenin (S552) and non-phospho β-catenin (S33/S37/T41), in 
both COX-1-/- and 2-/- mice models, compared to WT, during E19. ............................................ 53 
Figure 8: Differential gene expression in untreated and 1 µM PGE2 treated NE-4C stem cells. 55 
Figure 9: Gene expression in neuronally differentiated NE-4C stem cells. ................................ 57 
 
 
 
 
 
 
 
 
viii 
 
ABBREVIATIONS 
AA, Arachidonic acid 
ACC, Animal Care Committee 
ACTβ, β-actin 
AGE, Advanced glycation end-products 
ANOVA, Analysis of Variance 
APC, Adenomatous polyposis coli 
ASD, Autism Spectrum Disorders 
ATCC, American Tissue Culture Collection 
AutDB, Autism Database 
β-ME, β-mercaptoethanol 
BLAT, BLAST-like alignment tool 
Bp, Basepairs 
CAM, Cell Adhesion Molecule 
CAMK4, Calcium/calmodulin dependent protein kinase IV 
CaN, Calcineurin 
CCND, Cyclin D 
CDH, Cadherin 
cDNA, Complementary DNA 
DEPC, Diethyl pyrocarbonate 
CK1α, Casein kinase 1, alpha 
CK1ɛ, Casein kinase 1, epsilon 
CNTN2, Contactin 2 
CNTNAP, Contactin associated protein 
CNV, Copy number variation 
COX-1, Cyclooxygenase-1 
COX-2, Cyclooxygenase-2 
CREB, C-AMP response element-binding protein  
CT, Threshold Cycle 
CTNNB1, β-catenin gene  
DAAM1, Disheveled-associated activator of morphogenesis 1 
DHA, Docosahexaenoic acid 
DNA, Deoxynucleic acid 
DNase, Deoxyribonuclease 
dNTP, Deoxynucleotide triphosphates 
dsDNA, Double-stranded DNA 
Dvl, Dishevelled 
E, Embryonic day 
ECL, Enhanced chemiluminescence 
EDTA, Ethylenediaminetetraacetic acid 
EP, E-Prostanoid 
ESC, Embryonic stem cells 
FA, Fatty acid 
FC, Fold Change 
FDR, False discovery rate 
FMR1, Fragile X metal retardation 1 
ix 
 
FZD, Frizzled 
GABA, gamma-aminobutyric acid 
GAPDH, Glyceraldehyde 3-phosphate dehydrogenase 
gDNA, genomic DNA 
GLO1, Glyoxylase 1 
GO:BP, Go ontology: Biological Processes 
GPCR, G-protein-coupled receptors 
GRM5, Glutamate receptor, metabotropic 5 
GSK-3B, Glycogen synthase kinase 3β 
GWAS, Genome-Wide Association Studies 
HPRT, Hypoxanthine phosphoribosyl transferase 
HSC, Hematopoietic stem cells 
KEGG, Kyoto encyclopedia of genes and genomes 
KIF1B, kinesin family member 1 beta 
LRP, Lipoprotein receptor-related protein 
LTP, Long-term potentiation 
MECP2, Methyl-CpG binding protein 2 
MEEBO, Mouse exonic evidence based oligonucleotide 
MEM, Minimum essential medium  
MG, Methylglyoxal 
mGluR5, metabotropic glutamate receptor 5 
MMP9, matrix metalloproteinase 9 
MRI, Magnetic resonance imaging 
mRNA, messenger ribonucleic acid 
mTOR, mechanistic target of rapamycin 
MYT1L, Myelin transcription factor 1 like 
N, Total number 
NBM, Neurobasal Media 
NCBI, National center for biotechnology information 
NE-4C, Neuroectodermal stem cells 
NGS, Normal Goat Serum 
NLGN, Neuroligin 
NRXN, Neurexin  
NSAIDs, Non-steroidal anti-inflammatory drugs 
NT, Neurotransmitter 
OGS, Official gene symbol 
PBS, Phosphate buffered saline 
PCDH, protocadherin 
PCP, Planer cell polarity 
PCR, Polymerase chain reaction 
PGE, Prostaglandin type e 
PGE2, Prostaglandin E2 
PGES, Prostaglandin E synthase 
PGH2, Prostaglandin H2 
PGK1, Phosphoglycerate kinase 1 
PI-3K, Phosphoinositide 3-kinase 
x 
 
PKA, Protein kinase A 
PKB, Protein kinase B 
PLA2, Phospholipase A2 
PLC, Phospholipase C 
PPP3CA, Protein phosphatase 3 catalytic subunit alpha 
PTGS, Prostaglandin-Endoperoxide Synthase gene 
PTM, Post translational modification 
PUFAs, Polyunsaturated fatty acids 
qRT-PCR, Quantitative real-time polymerase chain reaction 
QC, Quality control 
RNA, Ribonucleic acid 
RNases, Ribonucleases 
RQ, Relative quantity 
S, Serine 
SCN1A, Sodium voltage-gated channel alpha subunit 1 
SDS-PAGE, Sodium dodecyl sulfate polyacrylamide gel electrophoresis  
SEMA5A, Semaphorin 5A 
SFRP, Secreted frizzled-related protein 
SHANK, SH3 and multiple ankyrin repeat domains protein 
SNP, Single nucleotide polymorphism 
SOX11, SRY-related HMG box 11 
SRY, Sex determining region of Y chromosome 
T, Threonine 
TAE, Tris-acetate-EDTA 
TBS-T, Tris-Buffered Saline and Tween 20 
TCF/LEF, T-cell factor/lymphoid enhancer-binding factor 
TF, Transcription factor 
TSC, Tuberous sclerosis complex 
TSC1/2, Tuberous sclerosis 1/2 
VPA, Valproic acid 
µM, Micromolar 
WB, Western blot 
Wnt, Wingless-type MMTV integration site family 
WT, Wild-type 
  
1 
 
1.0. INTRODUCTION 
1.1. Autism Spectrum Disorders 
Autism spectrum disorders (ASDs) are a highly complex set of neurodevelopmental 
disorders that manifest around the age of three and remain throughout an individual’s lifetime 
(Tamiji and Crawford, 2010b). ASDs are considered a spectrum of disorders consisting of sub-
categories in accordance with severity and types of symptoms. The most commonly cited 
behavioural characteristics for ASD include deficits in qualitative social interaction, impairments 
in language development and repetitive or restricted behaviour (Watts, 2008, Cao et al., 2012). 
Epidemiological data from 2010 suggests ASD prevalence is at an alarming one in 68 children of 
age 8 which is a 29% increase from previous estimates (Wingate et al., 2014). In addition, the 4-
5 times greater prevalence of ASD in boys than girls is still not well understood or explained 
(Fombonne, 2003, Wingate et al., 2014). Advancing ASD research to understand etiology, 
potential risks and modes of treatment has become important as these disorders impact an 
increasing number of individuals and families. Clinical observations of physiological and 
neurological characteristics of the brain of individuals with ASDs have been an important foray 
for understanding ASD etiology.    
Neuroanatomical studies have found larger brain size, or macrocephaly, early in postnatal 
life of children and adults with ASD (Courchesne and Pierce, 2005). More specifically, while 
being born with normal head circumference, larger brain volume followed by slower brain 
growth has been a predictor of later diagnosis of ASD in boys (Courchesne et al., 2001). 
Interestingly, the growth of the head is proportional to the severity of clinical symptoms in 
children with ASD (Courchesne et al., 2004). In addition, volumetric abnormalities have been 
observed in the amygdala, hippocampus, cerebral cortex, cerebellum and white matter 
(Courchesne et al., 2001, Sparks et al., 2002). One study has found that the size of the amygdala 
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in children becomes normal in adolescents, whereas the hippocampus remains enlarged 
throughout the life of individuals with ASD (Schumann et al., 2004). Furthermore, another study 
suggests that the frontal and temporal lobe may be affected more by the overgrowth than other 
regions of the brain (Carper et al., 2002). These changes have served as early warning signs 
before behavioural symptoms can confirm a diagnosis of ASD, allowing for early behavioural 
intervention. These structural changes can be helpful in predicting the behavioural symptoms 
corresponding to the abnormally sized brain regions (Ecker et al., 2013). However, it is 
important to examine neuronal function and the prenatal conditions in which these changes may 
arise.   
Dysfunction of synaptic signalling has been a key interest in ASD pathophysiology and a 
revealing phenotype of these disorders (Ecker et al., 2013). An imbalance between excitatory and 
inhibitory neural signals has become one of the most cited characteristics of ASD 
pathophysiology (Rubenstein and Merzenich, 2003, Ecker et al., 2013). Excitation and inhibition 
of neurons is governed by the action of neurotransmitters (NTs) γ-aminobutyric acid (GABA) 
and glutamate, respectively, and their corresponding receptors (Lee et al., 2016). In addition, 
brain imaging techniques have also revealed imbalances in the activity of serotonin, another NT, 
which governs mood and other complex behaviour (Ecker et al., 2013). In addition to the 
imbalance of signals, the synaptic function through which these signals are received has also 
been found to be altered (Ecker et al., 2013). Overall, these findings result in abnormal neural 
systems/circuits which makes up the connectome, a term for the neuronal pathways connecting 
the entire brain (Ecker et al., 2013). This has prompted the need for the characterization of the 
connectome in individuals with ASD using diffusion tensor imaging which provides an image of 
white matter tracts (Mevel et al., 2015). The study of structural and physiological phenotypes 
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have led to the identification of similarities between ASD and potential animal models for ASD 
(Lee et al., 2016). The continued effort to understand ASDs has indicated a complex interplay of 
several genetic and environmental processes resulting in the heterogeneous characteristics of 
ASDs (Zhang et al., 2009, Betancur, 2011, Ratajczak, 2011).  
 
1.2. ASD etiologies 
Several mechanisms underlying the etiology of ASDs have been described; one of the 
most studied is genetic mutations (Lichtenstein et al., 2010). Early epidemiological family 
studies indicated a high concordance rate in monozygotic twins, demonstrating an underlying 
genetic cause of Autism (Folstein and Rosen-Sheidley, 2001, Guo et al., 2011). These studies, 
however, have been criticized for being limited in scope and sample size (Mevel et al., 2015). 
Several genetic mutations including single nucleotide polymorphisms (SNPs), and rare inherited 
or de novo Copy-Number Variations (CNVs), which are large insertions or deletions, have been 
associated with ASD (Guo et al., 2011). Individuals with known SNPs or CNVs often display 
syndromic ASD which results in co-morbidities such as intellectual disability, epilepsy and 
schizophrenia, while genetically idiopathic ASDs are less severe and are non-syndromic (Basu et 
al., 2009, Betancur, 2011, Guo et al., 2011). Interestingly, SNPs and CNVs have been estimated 
to account for only 10-30% of all ASD cases, while the remaining are idiopathic or non-
syndromic (Guo et al., 2011, Kelleher et al., 2012, Szczaluba, 2014). Despite the limited ability 
for DNA sequence analysis to explain all ASD cases, these studies have identified a staggering 
number of ASD risk or associated genes.  
Genome-Wide Association Studies (GWAS), which compare polymorphisms and other 
mutations between two groups, have identified several cell adhesion molecules (CAMs) as ASD 
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susceptible genes. CAMs are cell surface proteins that bind to CAMs of neighboring cells or the 
extracellular matrix. The CAM proteins implicated in ASD primarily belong to the superfamily 
of cadherins (CDHs) and a subfamily known as protocadherins (PCDHs) (Guo et al., 2011, 
Redies et al., 2012, Talkowski et al., 2014). In particular, studies have identified genetic variants 
in a region containing the CDH8, 9 and 10 genes in ASDs (Wang et al., 2009, Pagnamenta et al., 
2011). These CDHs have been associated with several neuropsychiatric disorders and are 
important for neural tube development, neuronal migration, synaptic formation and synaptic 
modulation (Redies et al., 2012).  
An additional set of synaptic CAMs and scaffolding proteins have also been implicated in 
ASD pathophysiology (Bourgeron, 2009, Ecker et al., 2013, Gong and Wang, 2015). These 
proteins belong to three families; Neurexins (NRXNs), Neuroligins (NLGNs) and SH3 and 
multiple ankyrin repeat domain proteins (SHANKs), making up the NRXN-NLGN-SHANK 
pathway. More specifically, the ASD associated genes primarily include NRXN1, 2 and 3 along 
with another NRXN known as contactin associated protein-like 2 (CNTNAP2) (Autism Genome 
Project et al., 2007, Gauthier et al., 2011, Vaags et al., 2012); NLGN3 and 4 (Jamain et al., 
2003); and SHANK1, 2, and 3 (Moessner et al., 2007, Berkel et al., 2010, Sato et al., 2012). 
Together, these groups of proteins make up the protein complexes that ligate pre- and 
postsynaptic membranes (Bourgeron, 2009, Gong and Wang, 2015). NRXNs and NLGNs serve 
as adhesion molecules and localize in the pre- and postsynaptic membrane, respectively, to form 
the synaptic connection (Scheiffele et al., 2000, Autism Genome Project et al., 2007). 
Interestingly, the specific subtypes of NLGNs and NRXNs involved in the formation of the 
synapse can determine whether it will be excitatory or inhibitory (Dalva et al., 2007). 
Furthermore, mutations of SHANK3, a key scaffolding protein in the postsynaptic glutamatergic 
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signalling complex, have also been association with ASD (Durand et al., 2007). Furthermore, 
SHANK3 null mice not only display repetitive behaviour and deficits in social interaction, but 
also reduced glutamatergic (excitatory) synaptic transmission and long-term potentiation which 
are key processes for learning and memory (Peca et al., 2011, Yang et al., 2012). The formation 
and proper distribution of excitatory vs inhibitory synapses is a key event during brain 
development and strongly associated with ASD pathophysiology (Autism Genome Project et al., 
2007). 
Several other genes that have been associated with ASD can involve specific co-
morbidities, such as Tuberous Sclerosis 1 and 2 (TSC1 and 2; tuberous sclerosis), Fragile X 
Mental Retardation 1 (FMR1; intellectual disability), Methyl CpG binding Protein 2 (MECP2; 
Rett’s syndrome), and other genes resulting in epilepsy, neurofibromatosis and macrocephaly 
(Bourgeron, 2009, Ey et al., 2011). In addition, SEMA5A which encodes for Semaphorin 5A, a 
protein involved in axon guidance, has also been implicated in a GWAS (Weiss et al., 2009). 
While conservative estimates have listed 103 genes, up to 845 ASD susceptible genes have been 
identified along with 44 genomic loci associated with non-idiopathic ASDs (Basu et al., 2009, 
Betancur, 2011). For idiopathic ASDs, the role of the environment during early development has 
become particularly important due to the interaction between genes and the environment (Guo et 
al., 2011). Recent evidence suggests an etiological role of altered epigenetics as a result of 
maternal immune response and environmental exposure to pollutants in ASDs (Keil and Lein, 
2016, Nardone and Elliott, 2016). Thus, it is important to understand the interaction between 
environmental risk factors and gene expression which can have an impact on brain development 
and ASD pathogenesis.  
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1.3. Environmental insults during brain development 
During pre-and postnatal neural development, many widespread changes involving 
cellular organization, neuronal wiring and patterning (specialization and segmentation of brain 
regions) occur. These events rely on precisely regulated cellular and extracellular signalling 
molecules including morphogens which temporally and spatially regulate gene expression 
required for neuronal differentiation, migration, synaptogenesis and maturation (Inestrosa and 
Varela-Nallar, 2015, Gonzalez et al., 2016). Several environmental risk factors can interfere with 
these events resulting in abnormal brain development which can result in ASD pathogenesis. In 
particular, brain inflammatory immune response triggered by maternal or prenatal infections has 
been implicated in ASDs (Hwang and Chen, 2010, Ohkawara et al., 2015, Nardone and Elliott, 
2016). Other critical environmental factors include exposure to teratogens and oxidative stress 
(Chauhan and Chauhan, 2006, Tamiji and Crawford, 2010b, Dufour-Rainfray et al., 2011, 
Reynolds et al., 2012). Teratogens are chemicals that result in developmental anomalies in 
newborns depending on timing and dosage of prenatal exposure (Dufour-Rainfray et al., 2011). 
Due to the sequential nature of early brain development, time periods when the brain is 
particularly vulnerable to a specific type of insult are known as critical periods which can vary 
depending on the nature of the insult or teratogen (Courchesne and Pierce, 2005, Chaudhury et 
al., 2016). Teratogens can disrupt events taking place in varying rates and locations of the 
developing brain, some of these include cell division, migration and neurotransmission (Dufour-
Rainfray et al., 2011). With exposure during a critical period of brain development, several 
teratogens have been identified to cause autism-like characteristics, including valproic acid 
(VPA) (a mood stabilizer and antiepileptic drug), alcohol and thalidomide (Dufour-Rainfray et 
al., 2011, Middleton et al., 2012).  
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A particular teratogen known as misoprostol, a prostaglandin type E (PGE) analogue, has 
been found to result in abnormal brain development (Wong and Chan, 2005, Bos-Thompson et 
al., 2008, Miller et al., 2009). Normally, misoprostol is used to treat gastric ulcers as it decreases 
stomach acid secretion (Wong and Chan, 2005). However, prenatal exposure to misoprostol 
arises from attempts at using this drug to induce labour or terminate pregnancy (Miller et al., 
2009). Inappropriate administration of misoprostol, results in the child having Mobius syndrome 
and ASD like characteristics (Miller et al., 2009). Misoprostol exerts its action on cells thorough 
E-prostanoid (EP) receptors which normally bind to prostaglandin E2 (PGE2) which is the major 
endogenous lipid molecule in the brain (Bandim et al., 2003). The effects of misoprostol is an 
important finding as it suggests that lipid signalling pathways play an essential role in brain 
development, function and behaviour (Tamiji and Crawford, 2010b, Wong and Crawford, 2014). 
These results point towards a developmental role of lipids such as PGE2 and their connection 
with developmental brain disorders such as ASDs (Gharami et al., 2015, Guillermo et al., 2015, 
Schneider et al., 2016). 
 
1.4. The role of lipids in brain development 
Polyunsaturated fatty acids (PUFAs) are a key component of lipids found in the brain and 
include docosahexaenoic acid (DHA) and arachidonic acid (AA) fatty acids (FAs), these are 
derived from dietary omega-6 and -3 FAs and are the most abundant PUFAs in the brain (Tamiji 
and Crawford, 2010b, Brigandi et al., 2015). Along with playing an important role in cell 
membrane composition and fluidity, PUFAs and their derivatives interact with transmembrane 
signalling proteins such as G-Protein Coupled Receptors (GPCR) to modulate developmental 
events including synaptogenesis, neurogenesis, neurotransmission, neurotrophic factor 
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expression, signal transduction and gene expression (Schuchardt et al., 2010, Bradbury, 2011, 
Brigandi et al., 2015, Morgese and Trabace, 2016). More specifically, DHA has been found to 
play an essential role in the proliferation of neuronal cells, cell migration, differentiation and 
synaptogenesis during brain development (Gharami et al., 2015). Furthermore, DHA is highly 
concentrated in synapses for the maintenance of synaptic membrane potentials (Richardson, 
2004, Bradbury, 2011). One particular study has indicated that maternal supplementation of 
DHA and AA can enhance spatial learning and neuroprotection of brain lesions in adult rodent 
offspring (Godor-Kacsandi et al., 2013). Inappropriate dietary intake and imbalances of these 
lipids not only have an important role in brain development and behaviour, but also have been 
linked to neuropsychiatric disorders, including attention deficit disorder, Alzheimer’s disease, 
Schizophrenia and depression (Muller et al., 2002, Wenk, 2005, Young and Conquer, 2005, 
Colter et al., 2008).  
Mounting evidence has linked abnormal lipid intake and metabolism to developmental 
neuropsychiatric disorders, especially ASDs (Young and Conquer, 2005, Schuchardt et al., 2010, 
Tamiji and Crawford, 2010b). Several clinical studies have consistently found an imbalance or 
deficiency of PUFAs in blood samples of individuals with ASD compared to healthy groups 
(Vancassel et al., 2001, Bell et al., 2004, Sliwinski et al., 2006, Meguid et al., 2008, Wiest et al., 
2009, Bell et al., 2010, Mostafa et al., 2010, Brigandi et al., 2015). Interestingly, dietary 
supplementation of PUFAs has been shown to improve behaviour, especially eye contact, 
concentration and motor skills, as well as the balance of blood PUFAs in individuals with ASD 
(Meguid et al., 2008). Additionally, supplementation with omega-3 fatty acids has been shown to 
reduce hyperactivity associated with autism compared to placebo in a randomized double-blind 
study (Amminger et al., 2007). Interestingly, female mice that were fed an increased amount of 
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omega-6 PUFAs during gestation and lactation resulted in adult offspring exhibiting ASD like 
behaviour (Jones et al., 2013). Omega-6 PUFAs are used to synthesis AA which serves as a 
precursor for lipid derived signalling molecules, particularly PGE2 which has a diverse role in 
brain development and has been linked to ASD (Breyer et al., 2001). Taken together, these 
results not only indicate a key role of lipid molecules in ASD pathogenesis, but also the need to 
understand the role of downstream synthetic pathways and products of these molecules, such as 
PGE2. In addition to levels of PUFAs, other genetic and environmental factors have been shown 
to interfere with PGE2 levels resulting in abnormal brain development and ASD (Wu et al., 2007, 
Andreasson, 2010, Tamiji and Crawford, 2010b). 
 
1.5. The COX/PGE2 pathway  
PGE2 is primarily derived from AA which is released from the plasma membrane by 
phospholipase A2 (PLA2) (Nomura et al., 2011). Cyclooxygenase-1 and 2 (COX-1 and 2) 
facilitate the rate limiting step of converting AA into Prostaglandin H2 (PGH2) which is then 
converted to various prostanoids by prostaglandin E synthases (PGESs), including PGE2 which 
is the main prostanoid in the brain (Figure 1) (Coleman et al., 1994, Tamiji and Crawford, 2010b, 
Furuyashiki and Narumiya, 2011). The downstream pathway of PGE2 is facilitated by 4 isoforms 
of GPCRs known as EP1-4 (Coleman et al., 1994, Furuyashiki and Narumiya, 2011). 
Interestingly, functional EP receptors can be found both in the cell membrane and the nuclear or 
perinuclear membranes, thus PGE2 not only results in paracrine but also intracellular and 
autocrine signalling (Bhattacharya et al., 1999). Protein kinase A (PKA) and 
phosphotidylinositide 3-kinase (PI-3K) are key facilitators of EP receptor signal transduction 
(Andreasson, 2010). PGE2 is the main molecule involved in the COX induced immune response 
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as its pathway plays an important role in triggering inflammation and fever (Lazarus, 2006, 
Straccia et al., 2013). During an immune response, PGE2 levels rise due to an increased 
production and activity of COX-2 (Straccia et al., 2013). The role of triggering inflammation has 
direct implications for neurodevelopmental disorders associated with inflammation, caused by 
maternal and pre or postnatal infections, especially ASDs (Pepicelli et al., 2005, Smith, 2006, 
Benvenuto et al., 2009, Patterson, 2011). In non-neuronal cells, the PGE2 pathway has been 
involved in the modulation of cellular growth and motility (Raisz et al., 1993, Charo et al., 2013). 
In neuronal cells, this pathway has been shown to modulate a wide range of processes including 
synaptic maturation, transmission and plasticity (Chen and Bazan, 2005, Sang and Chen, 2006, 
Furuyashiki and Narumiya, 2011). PGE2 signaling also contributes to perinatal dendritic spine 
formation and learning and memory by regulating membrane excitability and plasticity in the 
hippocampus (Chen et al., 2002, Burks et al., 2007). Studies focusing on the inductive behaviour 
and function of COX enzymes have yielded further evidence for the role of PGE2 in the brain.  
The COX isoforms have distinct functions depending on differential cellular localization, 
regulatory mechanisms and expression levels throughout the body (Aid and Bosetti, 2011). 
While inducible by cytokines and growth factors in most tissues, COX-2 is constitutively 
expressed in the brain, especially during development, and COX-1 is constitutively expressed 
throughout the body (Vane, 1998, Maslinska et al., 1999, Amateau and McCarthy, 2004, Kirkby 
et al., 2012). In the adult brain COX-1 is primarily expressed in microglia and vascular cells 
(Hoozemans et al., 2001, Garcia-Bueno et al., 2009). COX-2, interestingly, is localized in post-
synaptic dendrites and excitatory terminals of neurons in the cortex, hippocampus and amygdala 
suggesting an important role in learning and memory through the modulation of neuronal 
transmission and plasticity (Wang et al., 2005, Hewett et al., 2006, Aid and Bosetti, 2011). 
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Interestingly, several over-the-counter anti-inflammatory drugs, known as Non-Steroidal Anti-
inflammatory Drugs (NSAIDs), function by inhibiting COX enzymes and have been used to 
study the function of COX enzymes in the brain (Silberstein and Stirpe, 2014). COX-2 selective 
inhibitors have been shown to significantly reduce postsynaptic membrane excitability and 
induction of long-term potentiation (LTP) in the hippocampus (Chen et al., 2002). Furthermore, 
this reduction in neuron excitability was reversed by PGE2 and not by other prostaglandins (Chen 
et al., 2002). Overall, expression of COX-2 in the cerebral cortex, hippocampus, amygdala, 
hypothalamus and spinal cord has been shown to play a role in fundamental brain processes such 
as synaptic remodelling, synaptic plasticity, memory consolidation, functional hyperemia and 
nerve transmission for fever and pain (Yamagata et al., 1993, Appleby et al., 1994, Breder et al., 
1995, Breder and Saper, 1996, Vane et al., 1998, Minghetti, 2004). The inflammatory, 
neurological and neurodevelopmental role of PGE2 and the environmental insults that can alter 
the levels of PGE2 point towards a link between the PGE2 pathway and ASD pathogenesis. 
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Figure 1: An overview of the prostanoid synthesis pathway and environmental interactions. 
The red arrows indicated the up or down regulatory responses during environmental changes 
such as immune response. As shown, misoprostol and inflammation can up-regulate or activate 
the PGE2 pathway which can also modulate the Wnt pathway and intracellular calcium 
homeostasis. This image has been modified from our previous work in Tamiji and Crawford 
(2010b). 
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1.6. The PGE2 pathway in ASDs  
Abnormalities in the PGE2 signaling pathway due to genetic or environmental causes 
have been linked to ASDs (Tamiji and Crawford, 2010b, Wong et al., 2014, Wong et al., 2015). 
In addition to environmental factors outlined above, our recent review discusses additional ASD 
environmental risk factors, including pollutants and toxins which can also alter PGE2 levels 
(Wong et al., 2015). Genetic mutations of enzymes involved in the synthesis of PGE2 have been 
implicated in several neurological disorders such as schizophrenia in which PLA2 mutations and 
abnormal expression has been found (Pae et al., 2004, Smesny et al., 2005). In individuals with 
Autism and Asperger’s syndrome, significantly increased PLA2 activity has been reported in 
blood cells (Bell et al., 2004). This increase in activity alters the functional capabilities of the cell 
membrane by reducing the amount of PUFAs incorporated into the membrane (Bell et al., 2004, 
Bell et al., 2010). Furthermore, several studies have implicated abnormal function and expression 
levels of COX-2 in patients with ASDs. More specifically, COX-2 immunoreactivity in the 
cortex has been found to be altered in individuals with Rett syndrome, a condition that exhibits 
ASD like behaviour (Kaufmann et al., 1997). The most striking evidence linking COX-2 and 
ASD has been provided by Yoo and colleagues who found polymorphisms in the COX-2 gene 
(PTGS2) in a large cohort of children with ASD but not in healthy parents (Yoo et al., 2008). 
Additional studies with a focus on the PGE2 pathway and its exposure have also indicated a 
significant role in neuronal development and ASD pathogenesis.  
The COX/PGE2 pathway is associated with several etiologies of ASD including genetic 
mutation, maternal diet, pollutant exposure, inflammation, neuronal transmission and plasticity. 
However, the molecular mechanisms by which PGE2 alters brain development are unclear. Our 
lab aims to understand the role of this pathway in neuronal development using cell culture and 
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mouse models. We have shown that PGE2 and, its analogue, misoprostol can alter intracellular 
and growth cone calcium homeostasis via PKA, resulting in neurite retraction in differentiating 
neuroblastoma cells (Tamiji and Crawford, 2010b, a, Davidson et al., 2016). More recently, we 
have demonstrated that higher levels PGE2 can not only accelerate proliferation and neuronal 
differentiation but also differentially regulate important genes in neuroectodermal (NE-4C) stem 
cells (Wong et al., 2016). Some of the developmental genes we found to be differentially 
regulated are known target genes of the Wingless-type MMTV integration site family (Wnt) 
pathway, a critical developmental pathway (Wong et al., 2016). This not only provided 
supporting evidence implicating Wnt signalling in ASD, but also for the role of PGE2 in brain 
development and ASD pathogenesis shown in our lab (Garber, 2007, Wang et al., 2010a, Cao et 
al., 2012, Wong et al., 2014). 
 
1.7. The Wnt pathway 
The Wnt pathway plays an overarching role in embryogenesis and is highly conserved 
throughout the animal kingdom as it is a key developmental morphogen (van Amerongen and 
Nusse, 2009, Solis et al., 2013). Wnt ligands are a large family of excreted glycoproteins that 
bind to Frizzled (FZD) receptors along with co-receptors such as LRP5/6 and tyrosine kinase 
receptors Ryk and Ror (Okerlund and Cheyette, 2011, Kuhl and Kuhl, 2013). Depending on the 
Wnt ligand and the receptor activated, Wnt signalling can activate two types of pathways; the 
canonical Wnt/β-catenin pathway (Figure 2) or the non-canonical pathway, which is independent 
of β-catenin and involves the release of Ca2+ stores (Okerlund and Cheyette, 2011). The 
canonical Wnt pathway utilizes β-catenin when activated as the central transducer protein, 
however, in the absence of a Wnt signal, β-catenin is continuously degraded by the destruction 
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complex (Okerlund and Cheyette, 2011). The destruction complex consists of four proteins that 
interact with β-catenin: Adenomatous polyposis coli (APC), Casein Kinase 1α (CK1α), Axin and 
glycoprotein synthase kinase-3 (GSK-3β) (Liu et al., 2002). The degradation of β-catenin is 
halted by the Wnt receptor activated protein Disheveled (Dvl) which causes the dissociation of 
the destruction complex (Okerlund and Cheyette, 2011). Upon disassociation, the discontinued 
degradation of β-catenin results in its accumulation and translocation into the nucleus where it 
binds heterodimers of T-Cell-specific/Lymphoid Enhancer-binding Factor (TCF/LEF) 
transcription factors (TFs) to induce transcription (Okerlund and Cheyette, 2011). Interestingly, 
two known post-translational modifications (PTMs) have been shown to indicate non-degradable 
or active β-catenin, this includes phosphorylation at serine (S)552 and non-phosphorylated at 
S33, S37 and threonine(T)41 (S33/S37/T41) (Wong et al., 2014). The downstream activation of 
gene expression results in a large variety of regulatory changes involving cell fate specification, 
polarity, differentiation, proliferation, migration, neuronal axon guidance and synapse formation 
(Logan and Nusse, 2004, Okerlund and Cheyette, 2011). 
The main role of the Wnt pathways is in early development, however, activation of this 
pathway in adults is often associated with cancer or adult stem cells (Clevers and Nusse, 2012, 
Mah et al., 2016). During early brain development, the expression of Wnt ligands is tightly 
regulated as specific ligand concentration gradients are crucial for appropriate spatial and 
temporal cell differentiation to occur (Kiecker and Niehrs, 2001, Solis et al., 2013). It has been 
demonstrated that treatment of a Wnt ligand and Wnt inhibitor on human embryonic stem cells 
(ESCs) results in the generation of endodermal/cardiac cells and neuroectodermal cells, 
respectively (Blauwkamp et al., 2012). Wnt ligands also regulate neuronal cell specialization, 
into dopamine neurons for example, and cell morphogenesis resulting in functional axons and 
16 
 
dendritic networks (Bodmer et al., 2009, Cajanek et al., 2009, Rosso and Inestrosa, 2013). 
Mounting evidence for a direct link between the canonical Wnt signalling pathway and ASD 
exists (Wassink et al., 2001, Zhang et al., 2009, Marui et al., 2010, Okerlund and Cheyette, 2011, 
Kalkman, 2012, Martin et al., 2013, Zhang et al., 2014).  
Several Wnt related genes have been implicated in ASD, especially the Wnt2 ligand gene 
(WNT2). With an earlier report by Wassink et al. (2001) and the identification of 9 SNPs in the 
WNT2 gene among 170 ASD patients compared to 214 controls, the WNT2 gene is considered a 
strong ASD candidate gene (Marui et al., 2010). Furthermore, mutations of the β-catenin gene 
(CTNNB1) have been identified in individuals with ASD (O'Roak et al., 2012). Several mouse 
knockout or knock-in studies of Wnt associated genes have indicated impaired behavioural traits 
similar to ASDs (Lijam et al., 1997, Kalkman, 2012, Dong et al., 2016). In particular, mouse 
studies have shown that altered functional levels of β-catenin, APC, Dvl1 and GSK-3 in the brain 
result in a significant increase in repetitive behaviour and decrease in social interaction (Lijam et 
al., 1997, Mines et al., 2010, Mohn et al., 2014, Dong et al., 2016). Interestingly, an ASD mouse 
model created from VPA exposure, a known teratogen, has been shown to activate the Wnt 
pathway by inhibiting the activity of GSK-3β (Hall et al., 2002, Bug et al., 2005, De Ferrari and 
Moon, 2006). Similarly, we have also shown a link between PGE2 and the Wnt pathway (Wong 
et al., 2014, Wong et al., 2016). 
 
1.8. Interaction between PGE2 and Wnt pathways  
In non-neuronal cells, a considerable amount of evidence indicates the existence of an 
interaction between PGE2 signalling and the Wnt pathway (Oshima et al., 2006, Goessling et al., 
2009, Liu et al., 2010). This interaction is primarily studied in cancer, particularly gastric 
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tumourigenesis, and stem cells (Oshima et al., 2006, Oshima et al., 2009, Yoshida et al., 2013). 
Goessling and colleagues (2009) have used Wnt reporter activity to demonstrate in vivo Wnt 
responsiveness to PGE2 exposure in hematopoietic stem cells (HSCs) of zebrafish. This was 
done in order to demonstrate the role of PGE2/Wnt in organ regeneration but warrants careful 
study due to risks of inducing tumourigenesis (Goessling et al., 2009). To date, there has not 
been any evidence for this interaction, not only in neuronal cells but also in the context of early 
development. In our lab we have shown for the first time that the PGE2 can alter Wnt pathways 
in our in vitro (Wong et al., 2014, Wong et al., 2016) and in vivo (Rai-Bhogal, 2016) models of 
the nervous system by altering β-catenin activity and Wnt target gene expression.  
Our research has shown that PGE2 can modify the activity of and cellular responses 
governed by the canonical Wnt pathway in NE-4C stem cells via PKA and PI-3K (Figure 2) 
(Wong et al., 2014, Wong et al., 2016). More specifically, PGE2 treatment of cells activated by a 
Wnt agonist (WntA) alters migration and proliferation of NE-4C cells (Wong et al., 2014). We 
also found increased levels of active β-catenin in the PGE2 treated WntA cells compared to 
WntA only treated cells. Furthermore, these changes in NE-4C cells were accompanied by 
altered expression of Wnt target genes that are important for cell proliferation, migration and 
PGE2 synthesis, including β-catenin (CTNNB1), PTGS2, cyclin D1 (CCND1) and matrix 
metalloproteinase 9 (MMP9) (Wong et al., 2014). Similarly, our in vivo study of embryonic 
exposure to PGE2, via maternal subcutaneous injection, also indicated differential expression of 
Wnt-target genes (Rai-Bhogal, 2016). The brains of offspring maternally exposed to PGE2 
during prenatal development also indicated an elevated level of active β-catenin (Rai-Bhogal, 
2016). Considering the neurodevelopmental processes that are regulated by PGE2 and Wnt 
signalling, the interactive link between them particularly important for the study of ASD. 
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Figure 2: A simplified overview of the Wnt/β-catenin (canonical) pathway. The destruction 
complex consists of axin, GSK-3β, CK1α and APC. If a Wnt signal is present, β-catenin 
accumulates and activates TFs TCF and LEF in the nucleus. This figure has been modified from 
our previous work in Wong et al. (2014). 
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1.9. Objectives 
Recent literature provides evidence for the diverse role of the COX-PGE2 pathway during 
healthy brain development and association of its abnormal signalling with ASD pathogenesis. 
Stemming from the current in vitro research emerging in our lab, the main objective of this thesis 
is to provide an in-depth global analysis of gene expression in the prenatal brain lacking COX-1 
and COX-2 enzymes producing PGE2. The goals of this research are the following:  
1. To provide novel insight on the transcriptome of the homozygous COX-1-/- and 2-/- male 
mice, during both embryonic day (E) 16 and 19. This study will investigate a global 
overview of differentially regulated genes and their associated functional signalling 
pathways in a model lacking PGE2 producing enzymes.  
2. To examine whether the cross-talk between the PGE2 and Wnt signalling pathway occurs 
in the prenatal brain of the COX-/- models. 
3. To characterize the expression level of selected differentially regulated genes in the 
existing in vitro cell models of undifferentiated and neuronally differentiated 
neuroectodermal NE-4C cells treated with PGE2. 
These results will provide the first in vivo evidence for the involvement of the COX/PGE2 
pathway in brain development and how it may contribute to the pathology of ASD. 
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1.10. Hypothesis 
We propose the following hypotheses for the studies presently conducted: 
Study 1: Microarray analysis in COX-/- mice models at E16 and E19 
1. Defect in the COX/PGE2 pathway results in abnormal expression of developmental genes 
linked to autism and important neurodevelopmental pathways. 
2. The comparisons in gene expression between E16 and E19 within each knockout will 
identify abnormalities in stage specific gene expression. 
3. A comparison of COX-1-/- to COX-2-/- prenatal brains will reveal distinct differentially 
expressed genes and pathways within both stages of development.  
4. Due to defective COX/PGE2 activity in the developing brain of our mouse models, we 
expect to find differential levels of active β-catenin and thus altered activity of the 
canonical Wnt pathway. 
Study 2: Gene expression of selected genes in PGE2 treated cell cultures 
1. Gene expression of selected developmental genes in our microarray study will also be 
affected in undifferentiated NE-4C stem cells and neuronally differentiated NE-4C cells 
exposed to PGE2.  
 
1.11. Experimental Model Systems 
For in vivo prenatal brain gene expression analysis, homozygous male mice lacking PGE2 
producing enzymes COX-1-/- or COX-2-/- (Taconic Biosciences) were used. These mice contain 
disruptions in the genomic DNA (gDNA) sequence of Ptgs1 or Ptgs2 genes encoding COX-1 or 
COX-2 enzymes, respectively (Langenbach et al., 1995, Yu et al., 2006). These mice models 
were compared to wild-type (WT) mice as controls. Due to the important role of critical periods 
in the manifestation and severity of neurodevelopmental disorders, we chose to observe gene 
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expression during E16 and 19. E16 spans the occurrence of neurogenesis in most brain regions, 
with especially elevated neurogenesis in the cerebral cortex, particularly in layers II/III, whereas 
E19 is the stage prior to birth with a slower rate of neurogenesis (Rodier, 1980, Rice and Barone, 
2000, Clancy et al., 2001). Furthermore, E16 has been identified as a critical period in which 
there is vulnerability for environmentally triggered hyperactivity and abnormal learning and 
memory in mice (Rodier, 1980).  
Several phenotypes of COX knockout mice or mice treated with COX inhibitory drugs 
have been characterized in the past. The reviews by Loftin et al. (2002), Morita (2002), and 
Langenbach et al. (1999a) outline many phenotypes across several organ systems where various 
prostanoids play important functional and developmental roles. While the function of COX-1 has 
been associated with gastric ulcerations, disruption of the COX-1 gene has only resulted in a 
significantly reduced stomach acid pH (Langenbach et al., 1995, Langenbach et al., 1999a). 
Interestingly, however, the inhibition of both COX enzymes using either two COX specific 
NSAIDs or a non-specific NSAID does result in gastric ulcerations in rats (Wallace et al., 2000). 
COX enzymes are also important for the female reproductive system; COX-1 deficiency results 
in a prolonged gestation period due to delayed parturition (Gross et al., 1998), while COX-2-/- 
female mice indicate more severe defects in ovulation, fertilization, implantation and 
decidualization (Dinchuk et al., 1995, Morham et al., 1995, Lim et al., 1997). Similarly, COX-1 
has not been shown to be critical for kidney development and function, while COX-2 is crucial 
for proper renal morphology and development, especially in postnatal life (Morham et al., 1995, 
Komhoff et al., 2000, Norwood et al., 2000). In addition to reduced intestinal tumorigenesis, 
COX-2 deficiency also results in protection against brain injury induced by ischemia (Oshima et 
al., 1996, Iadecola et al., 2001). Lastly, COX-2-/- mice also shown cardiac fibrosis, peritonitis, 
22 
 
and reduced ability for the liver to regenerate after hepatectomy (Langenbach et al., 1999b, 
Cheng et al., 2001, Rudnick et al., 2001). Overall, these studies have revealed several phenotypes 
and further indicate the more vital role of COX-2 over COX-1. Relevant for this study, however, 
are behavioural phenotypes which are not yet known and to be discovered.  
For in vitro experiments, we used NE-4C stem cells as the experimental model. These 
cells were obtained from American Tissue Culture Collection (ATCC). NE-4C cells are derived 
from primary brain cell cultures of E9 forebrain and midbrain vesicles of transgenic mouse 
embryos. These cells are known to mimic processes occurring in the developing brain including 
proliferation, migration, aggregation and differentiate into neuronal cells (Schlett and Madarasz, 
1997). These attributes make undifferentiated NE-4C stem cells a suitable model for 
understanding prenatal brain development. In addition to undifferentiated NE-4C stem cells, we 
also examined gene expression in neuronally differentiated NE-4C cells using differentiating 
media. Interestingly, we have previously found that the formation of neurospheres (3D 
aggregates of precursor neuronal cells), occurs two days earlier at Day 6 due to PGE2 treatment, 
while neurospheres formed at Day 8 in untreated differentiating cells, thus PGE2 accelerates 
differentiation (Wong et al., 2016). This was further demonstrated by an RNA marker known as 
Gfap, indicating the absence of astrocytes; and Mapt, indicating late neuronal cells, at Day 6 and 
8 for treated and untreated cells, respectively (Wong et al., 2016). Thus, to examine mature 
neurons for our study we examine Day 8 neuronally differentiated cells. 
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2.0. MATERIALS AND METHODS 
2.1. Animals 
Homozygous male mice deficient in COX-1 or COX-2 (COX-1-/- or COX-2-/-), and 
female heterozygous (COX-1+/- or COX-2+/-) mice were obtained from Taconic Biosciences 
(B6;129P2-Ptgs1tm1Unc and B6;129P2-Ptgs2tm1Unc). These mice contained disruptions in Ptgs1 or 
Ptgs2 genes, encoding for COX-1 or COX-2, respectively (Langenbach et al., 1995). Mice were 
acclimatized for one week at the York University animal facility with a 12 h light/dark cycle and 
ad libitum food and water. We used heterozygous females as homozygous females have 
substantially reduced fertility (Wang et al., 2010b). Wild-type (WT) mice (C57BL/6) were bred 
to obtain brain samples for control. For the microarray, we obtained three homozygous male 
offspring from each COX-1-/-, COX-2-/- and WT genotypes at days E16 and E19. COX-1-/- E16, 
COX-1-/- E19, COX-2-/- E16, COX-2-/- E19, WT E16 and WT E19 samples were collected. The 
animal protocol was approved by the Research Ethics Board of York University, Toronto.  
 
2.2. Genotyping 
gDNA was isolated from tail samples boiled in alkaline lysis reagent (25mM NaOH) and 
subsequently neutralized with Tris-HCL. The resulting gDNA was used to determine sex of the 
embryos using PCR with sex determining region Y (SRY) primers (Table 1). Knockout zygosity 
was determined using primer designs obtained from Taconic for both COX-/- mice (Table 1). The 
PCR reaction was carried out using dNTP (2500 µM of each), 5U/µL OneTaq DNA Polymerase 
and 5x OneTaq Reaction Buffer (BioLabs). 30 cycles of denature, anneal and extension; and a 
final extension step (Eppendorf Mastercycler) was used. 100 base pair (bp) ladder (Biolabs) and 
PCR products were resolved using a 1.2% agarose set in 1x Tris-acetate-EDTA (TAE) buffer 
with 2.5 µL of Ethidium Bromide for double-stranded DNA (dsDNA) labelling. 
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Table 1: Primers designed for genotyping using PCR. Forward (F) and reverse (R) primers 
are written in the 5’ to 3’ direction. To determine zygosity of the mutant mice, an additional 
primer was needed for amplification of the mutant version of the gene. 
Gene Sequence (5’3’) Amplicon 
Length (bp) 
SRY F - TCCCAGCATGCAAAATACAGAGATC 
R - TTGGAGTACAGGTGTGCAGCTCTAC 
300 bp 
COX-1 
Genotyping 
(Taconic) 
F(-/-) - CAGCCTCTGTTCCACATACAC 
R - CTGACTTTCTGAGTTGCCAAC 
F – GAGATGGCTGCTGAGTTGG 
(-/-): 700 bp,  
(+/-): 700 and 
600 bp 
COX-2 
Genotyping 
(Taconic) 
F(-/-) - ACGCGTCACCTTAATATGCG 
R - TCCCTTCACTAAATGCCCTC 
F - ACACACTCTATCACTGGCACC 
(-/-): 950 bp,  
(+/-): 950 and 
800 bp 
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2.3. Microarray 
Total RNA isolation from brain samples was carried out using the TRIzol method (Fisher 
Scientific). Sample collection and preparation was done by Ravneet Bhogal (Ph.D Candidate). 
The RNA for each sample was sent to Princess Margaret Genomics Centre (Toronto, Canada; 
www.pmgenomics.ca) for completion of microarray, quality control (QC) and statistical data 
analysis. Mouse WG-6 V2 BeadChip (Illumina) microarrays contained 45,281 target probes 
derived from the National Center for Biotechnology Information Reference Sequence (NCBI) 
RefSeq (Build 38 Release 22) (November 7, 2009), Mouse Exonic Evidence Based 
Oligonucleotide (MEEBO) and RIKEN FANTOM2 database. QC was done using R (v3.0.2) 
with the Bioconductor framework and LUMI packages installed; all data pertaining to each 
sample passed QC for further analysis. Subsequent analysis involved normalization steps using 
GeneSpring v12.6.1. Only probes that were above the 20th percentile of the distribution of the 
detected signal were included. Overall, the analysis indicated that the data was reliable, 
especially since housekeeping genes were found to be regulated as expected between 
comparisons. One way ANOVA with post-hoc test (Tukey HSD) was done to compare the data 
and the P-values were subsequently corrected using the Benjamini-Hochberg False Discovery 
Rate (FDR). The end results for the COX-/- experimental samples are indicated as a fold change 
(FC) with WT equaling 1.  
 
2.4. Bioinformatics 
Prior to bioinformatics, lists of genes that were statistically significant with FDR 
corrected P-value < 0.05 and absolute FC > 1.5 were compiled. In addition, we converted the 
gene names from Illumina gene IDs to Official Gene Symbol (OGS) using DAVID 
Bioinformatics Resources (http://david.abcc.ncifcrf.gov/). These cut-offs resulted in lists of 
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significantly differentially expressed genes for COX-1-/- E16, COX-1-/- E19, COX-2-/- E16 and 
COX-2-/- E19 (the list of all genes and FC can be found in Supplementary Table S1). To 
determine genes in common between knockouts within corresponding developmental stages, 
Venn diagrams were created using Venny 2.0 tool (http://bioinfogp.cnb.csic.es/tools/venny/). To 
obtain pathways in which the genes belonged, we carried out functional annotation using Gene 
Ontology: Biological Process (GO:BP) and Kyoto Encyclopedia of Genes and Genomes 
(KEGG) categories using DAVID Bioinformatics with the mouse BeadChip background list 
corresponding to the microarray chip used in this study (MouseWG-6_V2_0R2_11278593_A) 
(Huang da et al., 2009). Enrichment of genes belonging to a pathway was determined using 
Benjamini FDR corrected EASE score (one-tail Fisher Exact Probability Value) P-value < 0.1 
cut-off in DAVID. Only non-redundant annotations containing a gene count > 3 are reported. 
The annotations obtained from DAVID were divided using Venn diagram analysis to find 
pathways in common between COX-1-/- and 2-/- during E16, and COX-1-/- and 2-/- for E19. Genes 
associated with ASD in our lists were identified using Autism Database (AutDB) (Basu et al., 
2009) and cross referencing with additional genome wide studies of ASD patients. Much like 
that EASE score generated for the biological pathway analysis, we carried out hypergeometric 
tests using GeneProf (https://www.geneprof.org/GeneProf/tools/hypergeometric.jsp) for the ASD 
candidate genes found. A probability value cut-off of 0.005 was set, meaning that there would 
need to be a <0.5% chance of finding the same number of genes found with random sampling for 
the finding to be interesting. For this test, the total number of genes in the microarray (44622) 
and the total number of genes in AutDB (668) were used. Lastly, a KEGG pathway diagram was 
used to illustrate all three Wnt signalling pathways, indicating Wnt genes found in our COX-2-/- 
E16 mice and AutDB search.  
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2.5. Cell cultures 
Mouse NE-4C stem cells (ATCC) were kept in Minimum Essential Medium (MEM) 
from Eagle with 10% fetal bovine serum, 2 mM glutamine, 1 x penicillin-streptomycin mixture 
(Invitrogen). Cells were incubated in 95% humidity, 37°C and 5% CO2 (Varga et al., 2009). 
Plating was done on 0.01% poly-L-lysine (Sigma) coated 100 mm culture plates (BD Falcon) 
and sub-cultured at 1:5. After 24 hours the cells were treated with either control or experimental 
conditions and left to incubate for 24 hours. 1 µM PGE2 was added into the media for the 
experimental treatment, while media alone served as the control treatment. For the examination 
of undifferentiated cells, RNA/protein extraction was carried out after 24 hours of incubation in 
experimental or control treatments. 
For the induction of differentiation, the cells were dissociated from stock using 0.05% 
trypsin in ethylenediaminetetraacetic acid (EDTA), pelleted and re-suspended in MEM with 
conditions described above. 0.01% poly-L-lysine (Sigma) coated 35 mm tissue culture dishes 
(Sarstedt) were used for plating. Incubation was done in the conditions described above. 
Induction of differentiation of NE-4C cells was done on day 0 using Neurobasal media (NBM; 
supplemented with L-glutamate, 1x penicillin-streptomycin and 1x B-27; Invitrogen). 
Supplemental differentiating media was replaced every 2 days during the progression of 
differentiation. The treatments included only the media (control) and 1 µM PGE2 in media 
(experimental) from day 0 to 8. At maximum confluency, cells were lysed for RNA and protein 
extraction. Differentiation and sample preparation was done by Christine Wong (Ph.D 
Candidate). 
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2.6. RNA and protein isolation 
NucleoSpin®RNA/Protein-Kit (Macherey-Nagel) for RNA and protein extraction was 
used with the cell culture protocol provided by manufacturer (Kramer et al., 2010). Cell lysis 
buffer contained β-mercaptoethanol (β-ME) to inactivate Ribonucleases (RNases) present in the 
cell lysis. The lysis was filtered and homogenized by incorporation of 70% ethanol. RNA and 
protein were separated using a filter that is selective for RNA. Flow-through was set aside for 
protein purification. RNA was removed from the filter and the RNA was extracted through a 
series of filters and washes. In the process of RNA isolation, the samples were treated with 
deoxyribonuclease (DNase) enzyme and all samples were handled with RNase free lab-ware. 
Protein precipitator was added to the protein flow-through and upon washing with 50% ethanol 
and pellet drying, the protein was dissolved in 1% SDS with protease inhibitors (β-
glycerophosphate and sodium orthovandate). 
 
2.7. Reverse transcription and PCR 
Concentration of RNA samples were determined using RNA spectrophotometer analysis 
as done in previous studies (Kramer et al., 2010). The appropriate volume required for 4 µg of 
RNA was calculated and used for reverse transcription, this ensured that each reaction would 
result in the same amount of complementary DNA (cDNA). This is important to ensure that the 
variation in gene expression is not due to changes in loading of total RNA. As a precaution, 
isolated 4 µg RNA samples were treated with DNase I (0.2U of DNase I/µg of RNA and 1x 
DNase I reaction buffer at 37°C for 10 minutes) and, subsequently, 5 mM of EDTA was added 
for 10 minutes in 75°C to deactivate DNase I. Upon incubation (65°C for 5 minutes) with 0.04 
µg/µL Oligo(dT)18 and 2.5 mM dNTP (Biolabs) for annealing, 1x Reverse Transcriptase 
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Reaction Buffer and 200U of M-MuLV Reverse Transcriptase (Biolabs) were added to initiate 
the reaction. The reaction was carried out at 42°C for 60 minutes and 90°C for 10 minutes. 
Diethyl pyrocarbonate (DEPC)-treated water, RNase free pipette tips and tubes were used to 
avoid degradation of RNA.  
The completion of the reserve transcriptase reaction was confirmed by determining the 
presence of cDNA in the sample using PCR. The PCR reaction was carried out using dNTP 
(2500 µM of each), 5U/µL OneTaq DNA Polymerase and 5x OneTaq Reaction Buffer (BioLabs). 
GAPDH primers were used as this gene is a housekeeping gene and its presence can indicate the 
presence of cDNA. Final concentrations of 0.2 µM of forward (5’-CGGCCGCATCTTCTTGTG-
3’) and reverse (5’-ACACCGACCTTCACCATTTTG-3’) GAPDH primers were used. The 
reaction was carried out using an initial denature step; 30 cycles of denature, anneal and 
extension; and a final extension step in the Eppendorf Mastercycler. 100 bp ladder (Biolabs) and 
PCR products were resolved using a 1.2% agarose set in 1x TAE buffer with 2.5 µL of Ethidium 
Bromide for double-stranded DNA (dsDNA) labelling. 
 
2.8. Quantitative real-time PCR 
To validate genes of interest in our COX-/- mice brains and quantify gene expression in 
undifferentiated and differentiated NE-4C cell models, we carried out quantitative real-time PCR 
(qRT-PCR) of cDNA obtained from RT reactions as described previously (Wong et al., 2014). 
Sequences of primers used in the microarray were aligned using The UCSC Genome Browser 
Mouse BLAT search to precisely determine the genes for which the primers should be designed. 
Primers were designed using Primer Express Software v3.0. The primers chosen resulted in the 
optimal amplicon length of 50-150 bp. The primers were also void of repeat sequences, to 
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prevent non-specific binding; and contained exon-exon junctions in order to amplify only mature 
mRNA and not precursor mRNA or gDNA (Table 2). 
Two standard housekeeping control genes were used Phosphoglycerate Kinase 1 (PGK1) 
and hypoxanthine phosphoribosyl transferase (HPRT) (Wong et al., 2014). The expression of 
PGK1 and HPRT have been verified to be stable during development (Weingarten et al., 2012). 
We validated the expression of three genes in the COX-/- mice brains: Glyoxalase 1 (GLO1), 
Myelin Transcription Factor 1 Like (MYT1L) and Dishevelled-associated activator of 
morphogenesis 1 (DAAM1). For the examination of gene expression in our undifferentiated and 
differentiated NE-4C cell models, we quantified the expression of NRXN1, NRXN3, GLO1, 
Glutamate Receptor, Metabotropic 5 (GRM5), DAAM1 and Sry-related hmg box 11 (SOX11). 
qRT-PCR was conducted using a 7500 Fast Real Time PCR System (Applied Biosystems) as 
done previously (Wong et al., 2014). Equal loading of 3 µL cDNA was added for 20 µL SYBR 
green reactions per well. 
Quantitative values were obtained from the threshold cycle (CT) number. The raw CT 
values from experimental (COX-/- mice) and control (WT) samples were normalized using the 
geometric mean of the housekeeping genes, PGK1 and HPRT, to obtain the ∆CT values. The ∆CT 
values of the samples were compared with the control to obtain the relative quantity (RQ) value 
which represents the fold change expression of each target sample compared to control samples, 
this is known as the comparative CT method (Weingarten et al., 2012, Wong et al., 2014). Three 
independent experiments were carried out for statistical analysis. 
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Table 2: Primers designed for qRT-PCR. Forward (F) and reverse (R) primers are written in 
the 5’ to 3’ direction.  
Gene Sequence (5’3’) Amplicon 
Length (bp) 
HPRT F - TCCATTCCTATGACTGTAGATTTTAT 
R - AACTTTTATGTCCCCCGTTGACT 
75 
PGK1 F - CAGTTGCTGCTGAACTCAAATCTC 
R - GCCCACACAATCCTTCAAGAA 
65 
NRXN1 F - CCCGAATGTAGAAGGCAAAGA 
R - TGACACACGGAACCTGATATG 
78 
NRXN3 F - TGTGAACCAAGTACAGATAAGAGTC 
R - TTGGGCGCATGTGCTTTGTA 
71 
GLO1 F - CAAGACCCTGACGGCTACTG 
R - ATCCATTAATCCTCAAAGGCACA 
97 
GRM5 F - CATGGAGCCTCCGGATATAATG 
R - GTATCCAAGAGGAGTGACAACC 
89 
DAAM1 F - CTAAGCGAAGAGTTGCGGGA 
R - ACTCCAGCTCCGTCTCTACA 
115 
SOX11 F - CTCCATCACTCGGCTTTCTTAT 
R - GATACACTGCGTCTAGAGTTGG 
98 
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2.9. Western blot analysis 
 Total protein was extracted from WT and COX-/- brain tissue samples using the TRIzol 
method (Fisher Scientific). 40 ug samples were treated with loading buffer and resolved using 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred on to 
nitrocellulose membranes. We quantified two post-translationally modified forms of β-catenin to 
assay Wnt activity in our knockout models. These included non-phospho (Active) β-Catenin 
(S33/S37/T41) and phospho β-Catenin (S552), using a 1:1000 dilution of non-phospho (active) 
β-Catenin (S33/S37/T41) rabbit monoclonal (Cell Signaling #8814) and phospho β-Catenin 
(S552) (Cell Signaling #9566) antibodies, respectively. Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) (mouse 1:5000; Abcam #ab8245) was used as a stable housekeeping 
protein for loading control. With treatment of anti-rabbit or anti-mouse horseradish peroxidase-
conjugated secondary antibodies the membranes were incubated in enhanced chemiluminescence 
(ECL) substrate (Bio-Rad) and visualized using Geliance 600 Imaging System (Perkin Elmer). 
 
2.10. Statistics 
 Statistical Analysis for the qRT-PCR and western blot experiments for relative 
quantification of gene expression and β-catenin protein expression, respectively, was conducted 
with the Student’s t-Test. All numerical data is presented as mean±SEM determined from the 
average of three independent experiments. A P-value < 0.05 was considered significant. 
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3.0. RESULTS  
3.1. Study 1 
3.1.1. Differential gene expression impact and Venn diagram analysis in COX-1-/- or COX-2-/- 
mice models 
To obtain a broad overview of the impact on gene expression, we determined the total 
number of genes differentially expressed in all four COX knockout mice. We found a total of 
229, 323, 134 and 148 differentially expressed genes meeting our cut-offs in COX-1-/- E16, 
COX-2-/- E16, COX-1-/- E19 and COX-2-/- E19 mouse models, respectively (Figure 3). 
Supplementary Table S1 contains the entire list of genes and their FC for each knockout model. 
During E16, both COX-1-/- and COX-2-/- knockouts show a greater number of affected genes 
compared to E19. Generally, we also found more genes down-regulated than up-regulated in all 
mice models, although this is more apparent in the E16 mice. The COX-1-/- E16 differentially 
expressed genes include 163 down and 66 up-regulated genes, and COX-2-/- E16 indicates 208 
down and 115 up-regulated genes. Similarly, COX-1-/- E19 differentially expressed genes 
include 74 down and 60 up-regulated genes, while COX-2-/- E19 indicates 89 down and 59 up-
regulated genes. Overall, the knockout of either one of the COX enzymes has a greater impact on 
gene expression at the E16 stage with greater down-regulation than up-regulation, compared to 
E19. Furthermore, among all knockout conditions, COX-2-/- mice indicated the greatest number 
of differentially regulated genes. Thus, COX-2-/- has a greater impact than COX-1-/- during either 
stage of development, especially E16.  
Next, we aimed to determine the number of genes in common between and exclusive to 
COX-1-/- and COX-2-/- knockouts within either developmental stage. At E16, 157 affected genes 
were in common between COX-1-/- and COX-2-/- knockouts, while 72 and 166 genes were 
unique to COX-1-/- and COX-2-/- mouse models, respectively (Figure 4A). During E19, COX-1-/- 
and COX-2-/- indicated 69 genes in common, while 65 and 79 genes were unique to the 
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respective COX-/- models (Figure 4b). Overall, we observed a greater number of genes in 
common between the E16 than E19 COX-/- mice, indicating a more apparent functional overlap 
between the two enzymes during the earlier stage. Despite the overlap, the COX-2-/- mice also 
have a relatively high number of genes exclusively differentially expressed at E16. These results 
indicate a potentially greater impact on development in the COX-2 deficient mice than COX-1, 
with greater changes in gene expression in the earlier stage during which neurogenesis is rapidly 
occurring throughout the brain.  
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Figure 3: An overview of differentially expressed genes in COX-1-/- or COX-2-/- at E16 and 
E19. In the E16 stage we found 229 and 323 affected genes in the COX-1-/- and 2-/- mice, 
respectively. In the E19 stage, 134 and 148 genes were differentially expressed for COX-1-/- and 
2-/- mice, respectively. At stage E16, COX-1-/- has 163 and 66; and COX-2-/- has 208 and 115 
down- and up-regulated genes, respectively. At stage E19 however COX-1-/- has 74 and 60, 
while COX-2-/- has 89 and 59 down- and up-regulated genes, respectively. 
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Figure 4: Comparison of the number of genes differentially expressed between the COX-/- 
animals of stage E16 and E19. (A) At E16, COX-1-/- indicated 72 genes, COX-2-/- indicated 
166, and both have 157 genes in common. (B) At E19, COX-1-/- has 65 stage-specific genes, 
while COX-2-/- has 79 genes and both have 69 genes in common. Diagrams were created using 
Venny 2.0 (http://bioinfogp.cnb.csic.es/tools/venny/). 
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3.1.2. Functional pathway analysis 
In order to gain insight into the biological and neurodevelopmental roles of the affected 
genes, we used GO:BP and KEGG databases to discover enriched functional pathways (see 
methods for detailed criteria). The generated pathway lists for both COX knockouts at either E16 
or 19 were put through venn diagram analysis to determine pathways in common between the 
knockout models of the COX isozymes. At the E16 stage, 13 pathways exclusively enriched in 
the COX-1-/- knockout were found, 8 of which include at least one gene previously implicated in 
ASD (Table 3A, ASD genes in bold). The ASD genes containing functional pathways include: 
regulation of neurological system process (GO:0031644, P = 0.002), long-term potentiation 
(LTP) (KEGG: mmu04720, P = 0.008), adipocytokine signaling pathway (KEGG: mmu04920, P 
= 0.041), secretion (GO:0046903, P = 0.047), lipid biosynthetic process (GO:0008610, P = 
0.047), blood vessel development (GO:0001568, P = 0.071), microtubule-based process 
(GO:0007017, P = 0.093) and vesicle-mediated transport (GO:0016192, P = 0.095). In the COX-
2-/- knockout of the E16 stage, 14 pathways were exclusively affected, 10 of which included at 
least one gene previously implicated in ASD (Table 3B, ASD genes in bold). The functional 
pathways containing an ASD gene include: Wnt signaling (KEGG: mmu04310, P = 0.023), 
DNA metabolic process (GO:0006259, P = 0.031), chordate embryonic development 
(GO:0043009, P = 0.035), skeletal system development (GO:0001501, P = 0.036), intracellular 
transport (GO:0046907, P = 0.043), axon guidance (KEGG: mmu04360, P = 0.044), regulation 
of translation (GO:0006417, P = 0.075), long-term depression (KEGG: mmu04730, P = 0.089) 
and negative regulation of apoptosis (GO:0043066, P = 0.094). Lastly, 10 pathways were 
determined to be in common between both COX-1-/- and COX-2-/- mouse models of the E16 
stage (Table 3C, ASD genes in bold). From the common pathways, the 7 consisting of at least 
one ASD risk gene include: transmission of nerve impulse (GO:0019226, P = 0.00034; 0.011), 
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regulation of synaptic transmission (GO:0050804, P = 0.001; 0.071), cell cycle processes 
(GO:0007049, P = 0.045; 0.069), heart development (GO:0007507, P = 0.050; 0.071), cell 
motion/migration (GO:0006928; 0016477, P = 0.063; 0.088) and transcription (GO:0006350, P 
= 0.080; 0.097). Overall, these pathways, especially synaptic transmission which was found in 
both E16 COX-/- mice, are crucial for brain development and behaviour. Interestingly, we found 
Wnt signalling exclusively enriched with 8 genes in the COX-2-/- mice during E16. 
At the E19 stage, 8 pathways were enriched in COX-1-/- mice, from these, 3 include at 
least one ASD risk gene (Table 4A, ASD genes in bold). The ASD gene containing pathways 
include transmission of nerve impulse (GO:0019226, P = 0.014), secretion (GO:0046903, P = 
0.051) and induction of apoptosis (GO:0006917, P = 0.086). In the COX-2-/- mice, 4 of the 6 
functional pathways included at least one ASD risk gene (Table 4B, ASD genes in bold), these 
include sensory perception of sound (GO:0007605, P = 0.014), lipid transport (GO:0006869, P = 
0.040), tissue morphogenesis (GO:0048729, P = 0.066) and intracellular protein transport 
(GO:0006886, P = 0.099). In addition, there were three pathways enriched with critical 
neurological functions and ASD candidate genes that were common between COX-1-/- and 
COX-2-/- models at E19 (Table 4C, ASD genes in bold). These affected pathways are involved in 
lipid localization (GO:0010876, P = 0.046; 0.009), neural tube development (GO:0035295, P = 
0.087; 0.029), and morphogenesis of branching structure (GO:0001763, P = 0.046; 0.048). 
Overall, a greater number of pathways were enriched in both COX knockouts of the 
earlier stage of development during which neurogenesis is active in most regions of the prenatal 
brain. This is consistent with the greater number of genes differentially expressed in the E16 
knockouts and provides further evidence that this earlier developmental stage may be more 
critical for normal COX-PGE2 activity. Furthermore, most of the enriched pathways included 
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ASD risk genes, indicating that evidence for the potential role of aberrant COX-PGE2 pathway in 
the pathogenesis of ASDs. With our previous research, enrichment of the Wnt signaling pathway 
in the COX-2-/- E16 model is of particular importance (this finding is further outlined in section 
3.1.4. of the Results). 
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Table 3: Enriched GO:BP and KEGG pathways affected in the COX-1-/- and COX-2-/- mice 
at E16. The chart shows affected biological pathways (A) exclusive to COX-1-/- E16, (B) COX-
2-/- E16 and (C) common between COX-1-/- and 2-/-. The database category for GO and KEGG, 
Benjamini FDR corrected EASE score P-value, gene count and gene lists are listed. Bold genes 
are ones that were found in our subsequent AutDB analysis. Both COX-/- enzymes exhibit 
important developmental pathways including LTP, synaptic transmission, cell division, Wnt 
signalling pathway (red), cell migration and axon guidance. 
(A) COX-1-/- E16 only 
Database 
Category 
Biological Pathways Corre
ct-ed 
P-
value 
Gene 
Count 
Differentially Expressed Genes 
GOTERM_
BP_FAT 
Regulation of neurological system process 
(GO:0031644) 
0.002 7 SYP, GRM5, GRIA2, NCDN, CSPG5, PPP3CA, CHRNA3 
GOTERM_
BP_FAT 
Regulation of cell morphogenesis 
(GO:0022604) 
0.005 6 EPB4.1L2, PALM, MAPT, CHRNA3, MYH10, THY1 
KEGG_PA
THWAY 
Long-term potentiation (mmu04720) 0.008 5 GRM5, GRIA2, CAMK4, CAMK2B, PPP3CA 
GOTERM_
BP_FAT 
Female gamete generation (GO:0007292) 0.026 4 REC8, ZMIZ1, HEXB, ATM 
KEGG_PA
THWAY 
Adipocytokine signaling pathway 
(mmu04920) 
0.041 4 IRS2, PRKAG2, ACSL6, CAMKK2 
GOTERM_
BP_FAT 
Secretion (GO:0046903) 0.047 7 SYT4, HPS1, NRXN1, VPS33A, CHRNA3, EXOC6B, 
MYH10 
GOTERM_
BP_FAT 
Lipid biosynthetic process (GO:0008610) 0.047 8 AGPAT5, INSIG2, HEXB, PRKAG2, MBOAT2, PBX1, 
ALG9, DHCR24 
KEGG_PA
THWAY 
Viral myocarditis (mmu05416) 0.070 4 ACTB, DAG1, CXADR, MYH10 
GOTERM_
BP_FAT 
Blood vessel development (GO:0001568) 0.071 7 MEF2C, SEMA5A, RECK, HIF1A, IL18, ZMIZ1, THY1 
GOTERM_
BP_FAT 
Regulation of kinase activity 
(GO:0043549) 
0.073 6 PKIG, DGKH, PRDX2, ZEB2, CHRNA3, THY1 
GOTERM_
BP_FAT 
Response to oxidative stress 
(GO:0006979) 
0.085 4 HIF1A, GPX8, PRDX2, DHCR24 
GOTERM_
BP_FAT 
Microtubule-based process (GO:0007017) 0.093 6 SPC25, KIF1B, MTAP2, MAPT, TUBB6, HOOK3 
GOTERM_
BP_FAT 
Vesicle-mediated transport (GO:0016192) 0.095 10 SYP, GRIA2, SYT4, CAP1, NAPB, VPS33A, HOOK3, 
EXOC6B, MYH10, TRAPPC2 
(B) COX-2-/- E16 only 
GOTERM_
BP_FAT 
Sulfur metabolic process (GO:0006790) 0.015 6 ADI1, AHCY, SEPP1, DCN, TPMT, MGST1 
KEGG_PA
THWAY 
Wnt signaling pathway (mmu04310) 0.023 8 SFRP1, CCND2, CSNK1E, SFRP2, GSK3B, PPP3CA, 
DAAM1, ACTB 
GOTERM_
BP_FAT 
Somitogenesis (GO:0001756) 0.028 4 SFRP1, SFRP2, FOXC2, ZEB2 
GOTERM_
BP_FAT 
Regulation of protein complex 
disassembly (GO:0043244) 
0.031 4 MTAP2, MAPT, TMOD3, CLASP1 
GOTERM_
BP_FAT 
DNA metabolic process (GO:0006259) 0.031 13 RAD23B, UBE2A, MELA, LOC100046025, ESCO2, 
MCM6, RPA3, GIN1, UBE2N, BCL11B, RRM1, MLL1, 
NFIB 
GOTERM_
BP_FAT 
Chordate embryonic development 
(GO:0043009) 
0.035 13 NRP, UBE2A, HIF1A, SFRP1, SFRP2, ZMIZ1, TGFBR2, 
TSC2, FOXC2, ZEB2, KEAP1, DLK1, MYH10 
GOTERM_
BP_FAT 
Skeletal system development 
(GO:0001501) 
0.036 10 MEF2C, RAI1, HIF1A, HEXB, TGFBR2, SOX5, FOXC2, 
DLK1, SOX6, COL5A2 
GOTERM_
BP_FAT 
Intracellular transport (GO:0046907) 0.043 13 AP1B1, NAPB, HOOK3, KIF1B, SRPR, GSK3B, 
ARCN1, TSC2, PPP3CA, KPNA2, SRP9, TRAPPC2, 
MYH10 
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KEGG_PA
THWAY 
Axon guidance (mmu04360) 0.044 6 NGEF, GNAI1, PLXNA2, CFL2, GSK3B, PPP3CA 
KEGG_PA
THWAY 
Tight junction (mmu04530) 0.046 6 ACTB, EPB4.1L2, EPB4.1L1, GNAI1, JAM3, MYH10 
GOTERM_
BP_FAT 
Regulation of translation (GO:0006417) 0.075 5 TNRC6C, RBM8A, PAIP1, TIA1, SRP9 
KEGG_PA
THWAY 
P53 signaling pathway (mmu04115) 0.077 4 CCND2, TSC2, CCNG1, CCNG2 
KEGG_PA
THWAY 
Long-term depression (mmu04730) 0.089 4 GRM5, GRIA2, GNAI1, GUCY1A3 
GOTERM_
BP_FAT 
Negative regulation of apoptosis 
(GO:0043066) 
0.094 8 BCL11B, GSK3B, FCER1G, FOXC2, PRDX2, GLO1, 
DNAJC5, DHCR24 
(C) Common pathways for E16 COX-1-/- (top) and COX-2-/-(bottom) 
GOTERM_
BP_FAT 
Gas transport (GO:0015669) 0.000 4 HBB-BH1, HBB-B1, HBA-X, HBB-Y 
0.001 4 HBB-BH1, HBB-B2, HBA-X, HBB-Y 
GOTERM_
BP_FAT 
Transmission of nerve impulse 
(GO:0019226) 
0.000 11 SYP, SCN1A, KIF1B, GRIA2, LOC100047888, CAMK4, 
SYT4, HEXB, NRXN1, PPP3CA, CHRNA3 
0.011 10 SYT1, SCN1A, KIF1B, GRIA2, LOC100047888, HEXB, 
NRXN1, SV2A, PPP3CA, USP14 
GOTERM_
BP_FAT 
Regulation of synaptic transmission 
(GO:0050804) 
 
0.001 7 SYP, GRM5, GRIA2, NCDN, CSPG5, PPP3CA, CHRNA3 
0.071 5 GRM5, GRIA2, NCDN, CSPG5, PPP3CA 
GOTERM_
BP_FAT 
Cell cycle process 
(GO:0022402/0007049) 
 
0.045 10 SPC25, REC8, SIN3A, ANAPC5, CAMK2B, UBE2I, 
PPP3CA, CCNG2, STAG2, MYH10 
0.069 16 SF1, CETN2, UBE2I, CCNG1, CCNG2, ESCO2, MCM6, 
MLF1, SPC25, REC8, CCND2, GSK3B, CLASP1, 
PPP3CA, STAG2, MYH10 
GOTERM_
BP_FAT 
Cytoskeleton organization (GO:0007010) 
 
0.015 10 EPB4.1L2, PALM, SPC25, EPB4.1L1, MTAP2, MAPT, 
CAP1, HOOK3, MYH10, THY1 
0.017 12 EPB4.1L2, PALM, SPC25, EPB4.1L1, NAV1, MTAP2, 
LIMCH1, MAPT, DAAM1, CDC42BPB, HOOK3, 
MYH10 
GOTERM_
BP_FAT 
Hemopoietic or lymphoid organ 
development (GO:0048534) 
 
0.016 9 EGR1, HIF1A, BCL11B, ADAM17, PBX1, PRDX2, HBB-
B1, VPS33A, HBA-X 
0.076 9 HIF1A, BCL11B, TGFBR2, PRDX2, SOX6, HBB-B2, 
HBA-X, MLL1, MLF1 
GOTERM_
BP_FAT 
Chromosome segregation (GO:0007059) 
 
0.041 4 SPC25, REC8, UBE2I, STAG2 
0.088 4 SPC25, REC8, UBE2I, STAG2 
GOTERM_
BP_FAT 
Heart development (GO:0007507) 
 
0.050 7 MEF2C, HIF1A, ZMIZ1, CXADR, ATM, CHRNA3, 
MYH10 
0.071 8 MEF2C, HIF1A, ZMIZ1, TGFBR2, TSC2, FOXC2, 
SOX6, MYH10 
GOTERM_
BP_FAT 
Cell motion/migration 
(GO:0006928/0016477) 
0.063 9 SEMA5A, NRP, KLF7, HIF1A, CNTN2, ADAM17, ZEB2, 
CAP1, MYH10 
0.088 8 NRP, HIF1A, NAV1, PLXNA2, CNTN2, FCER1G, ZEB2, 
MYH10 
GOTERM_
BP_FAT 
Transcription (GO:0006350) 
 
0.080 28 ITGB3BP, MEF2C, BACH1, BACH2, ZFP68, ZEB2, 
KEAP1, TFAM, SIN3A, BCL11B, ACTL6B, GTF3C2, 
TWISTNB, EGR1, KLF7, TAF6, SOX11, SNAPC3, 
HMG20A, MCM6, MYT1L, HIF1A, UBTF, ZMIZ1, 
PBX1, TRAPPC2, NFIB, PBX4 
0.097 36 BACH1, MEF2C, POU6F1, ZMYND11, BACH2, SOX5, 
ZEB2, KEAP1, MED23, SOX6, ZBTB17, 
1810035L17RIK, MLF1, BCL11B, ZFP131, PHTF1, 
GTF3C2, MLL1, KLF7, SOX11, SNAPC3, SF1, ZFP606, 
LOC100046343, SREBF2, MCM6, MYT1L, ZFP286, 
HIF1A, EBF3, ZMIZ1, FOXC2, ST18, TRAPPC2, NFIB, 
PBX4 
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Table 4: Enriched GO:BP and KEGG pathways affected in the COX-1-/- and COX-2-/- at 
E19. Pathways (A) exclusive to COX-1-/- E19, (B) exclusive to COX-2-/- E19 and (C) common 
between COX-1-/- and 2-/- are shown. For each pathway, the database category, Benjamini FDR 
corrected EASE score P-value, gene count and gene list is presented. Bolded are genes are ASD 
candidate genes found in our subsequent AutDB analysis. Both COX-/- enzymes exhibit 
important developmental pathways including regulation of transcription, nerve transmission, 
lipid biosynthesis, vesicle secretion and forebrain development. 
(A) COX-1-/- E19 only 
Database 
Category 
Biological Pathways Corre
ct-ed 
P-
value 
Gene 
Count 
Differentially Expressed Genes 
GOTERM_
BP_FAT 
Regulation of transcription from RNA 
polymerase II promoter (GO:0006357) 
0.005 11 TXNIP, EGR1, FOS, CEBPB, SOX11, NKX6-2, PKIG, 
NKX2-1, ST18, KLF4, PITX2 
GOTERM_
BP_FAT 
Glucose metabolic process (GO:0006006) 0.010 5 PPP1CA, UEVLD, PHKB, PKM2, PYGB 
GOTERM_
BP_FAT 
Transmission of nerve impulse 
(GO:0019226) 
0.014 6 NRXN2, CAMK4, NRXN3, NKX6-2, HEXB, CHRNA3 
KEGG_PA
THWAY 
Focal adhesion (mmu04510) 0.029 5 ACTB, PPP1CA, GRLF1, CAPN2, COL5A2 
GOTERM_
BP_FAT 
Lipid biosynthetic process (GO:0008610) 0.031 6 AGPAT5, LASS4, INSIG2, HEXB, MBOAT2, ALG9 
GOTERM_
BP_FAT 
Secretion (GO:0046903) 0.051 5 NRXN2, NRXN3, STXBP2, VPS33A, CHRNA3 
GOTERM_
BP_FAT 
Forebrain development (GO:0030900) 0.084 4 FEZF1, GRLF1, NKX2-1, PITX2 
GOTERM_
BP_FAT 
Induction of apoptosis (GO:0006917) 0.086 4 SERINC3, CEBPB, APOE, PHLDA3 
(B) COX-2-/- E19 only 
GOTERM_
BP_FAT 
Translation (GO:0006412) 0.003 8 RPL30, RPS3A, MRPL55, WARS2, LARS2, IARS2, RPS2, 
RPL29 
GOTERM_
BP_FAT 
Sensory perception of sound 
(GO:0007605) 
0.014 4 MYO6, CDKN1B, HEXB, GJB2 
GOTERM_
BP_FAT 
Sulfur metabolic process (GO:0006790) 0.021 4 ADI1, MTHFD1, AHCY, MGST1 
GOTERM_
BP_FAT 
Lipid transport (GO:0006869) 0.040 4 SORL1, ATP10D, GLTPD1, ATP8A1 
GOTERM_
BP_FAT 
Tissue morphogenesis (GO:0048729) 0.066 5 SFRP1, TSC2, GRLF1, PBX1, PITX2 
GOTERM_
BP_FAT 
Intracellular protein transport 
(GO:0006886) 
0.099 5 MYO6, SRPR, ARCN1, TSC2, IPO9 
(C) Common pathways for E19 COX-1-/- (top line) and COX-2-/- (bottom line) 
GOTERM_
BP_FAT 
Lipid localization (GO:0010876) 
 
0.046 4 APOE, HEXB, SCP2, GLTPD1 
0.009 5 HEXB, SORL1, ATP10D, GLTPD1, ATP8A1 
GOTERM_
BP_FAT 
Tube development (GO:0035295) 0.087 5 SEMA5A, PPP1CA, GRLF1, NKX2-1, PITX2 
0.029 6 SEMA5A, LHX1, TSC2, GRLF1, PBX1, PITX2 
GOTERM_
BP_FAT 
Morphogenesis of a branching structure 
(GO:0001763) 
0.046 4 SEMA5A, PPP1CA, SFRP1, PITX2 
0.048 4 SEMA5A, SFRP1, PBX1, PITX2 
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3.1.3. ASD risk genes in COX-/- mice 
Due to the important role of the COX-PGE2 pathway in the brain and ASD pathogenesis, 
we used AutDB and additional human genome wide ASD studies to identify ASD risk or 
candidate genes in our knockout models (see methods) (Table 5). At the E16 stage, 23 out of 229 
differentially expressed genes were identified as ASD risk genes (19 down- and 4 up-regulated) 
in the COX-1-/- model, while 37 out of 323 differentially expressed genes (29 down- and 8 up-
regulated) were identified as ASD candidate genes for the COX-2-/- model. During E19, 7 out of 
134 differentially expressed genes were ASD risk genes (5 down- and 2 up-regulated) in the 
COX-1-/- model and 10 out of 148 differentially expressed genes (8 down- and 2 up-regulated) 
were identified as ASD risk genes in the COX-2-/- model. The enrichment of these ASD genes 
was verified using a hypergeometric tests (see methods) resulting in values of 9.68e-13, 1.24e-21, 
4.18e-3 and 8.47e-5 for COX-1-/- E16, COX-2-/- E16, COX-1-/- E19 and COX-2-/- E19, 
respectively. These probabilities indicate that there is a very low chance that the number of ASD 
genes found in all conditions can be due to random sampling and thus ASD genes are enriched in 
these knockouts. Overall, most of the ASD genes identified were down-regulated with a greater 
number enriched in the COX knockouts, especially COX-2-/- mice, of the E16 developmental 
stage. Some of the genes that we found to be noteworthy are MYT1L, in both COX-1-/- mice; 
TSC2, in both COX-2-/- mice; MEF2C, in both E16 knockouts; and MDGA2, in both E16 
knockouts. Taken together, knockout of COX enzymes, especially COX-2, results in aberrant 
ASD risk gene expression of ASD risk genes indicating that this knockout model is useful for the 
study of ASD. 
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Table 5: ASD associated genes differentially expressed in (A) COX-1-/- E16, (B) COX-2-/- 
E16, (C) COX-1-/- E19 and (D) COX-2-/- E19. Along with official gene symbol, gene name, 
fold change (FC), chromosome location and number of gene association studies are listed from 
data found in the AutDB along with our own research findings of GWAS in humans. 
(A) COX-1-/- E16 
Official 
Gene 
Symbol 
Gene Name Fold 
Cha
nge  
Huma
n 
Cytob
and  
Number of 
Studies listed 
in AutDB 
and 
additional 
autism 
studies 
DAVID Biological Process 
MYT1L Myelin transcription factor 1-like -5.48 2p25.3 8(AutDB) Transcription (GO:0006350) 
PRKAG2 protein kinase, AMP-activated, 
gamma 2 non-catalytic subunit 
-3.97 7q36.1 Voineagu et al. 
(2011) 
Fatty acid biosynthetic process (GO:0006633) 
MEF2C myocyte enhancer factor 2C -2.85 5q14 14(AutDB), Hu 
et al. (2009) 
Vasculature development (GO:0001944) 
Transcription (GO:0006350) 
Apoptosis (GO:0006915) 
GRM5 Glutamate receptor, metabotropic 
5 
-2.81 11q14.
2-
q14.3 
3(AutDB) Behavior (GO:0007610) 
Learning or memory (GO:0007611) 
Regulation of synaptic plasticity (GO:0048167) 
B3GALT6 similar to UDP-Gal:betaGal beta 
1,3-galactosyltransferase, 
polypeptide 6; UDP-Gal:betaGal 
beta 1,3-galactosyltransferase, 
polypeptide 6 
-2.70 1p36.3
3 
Nishimura et al. 
(2007) 
Polysaccharide biosynthetic process (GO:0000271) 
Glycosylation (GO:0070085) 
BACH1 BTB and CNC homology 1 -2.24 21q22.
11 
Voineagu et al. 
(2011) 
Transcription (GO:0006350) 
KIF1B kinesin family member 1B -1.97 1p36.2 Hu et al. (2006) Synaptic transmission (GO:0007268) 
Neuromuscular synaptic transmission 
(GO:0007274) 
Anterograde axon cargo transport (GO:0008089) 
MDGA2 MAM domain containing 
glycosylphosphatidylinositol 
anchor 2 
-1.81 14q21.
3 
5(AutDB), 
Voineagu et al. 
(2011) 
Spinal cord development (GO:0021510) 
Neuron differentiation (GO:0030182) 
PCDHA7 Protocadherin alpha 7 -1.79 5q31 3(AutDB) Cell adhesion (GO:0007155) 
CAMK4 Calcium/calmodulin-dependent 
protein kinase IV 
-1.75 5q21.3 1(AutDB) Synaptic transmission (GO:0007268) 
Phosphorylation (GO:0016310) 
Neurological system process (GO:0050877) 
Nuclear transport (GO:0051169) 
CDH8 cadherin 8, type 2 -1.72 16q22.
1 
7(AutDB) Cell adhesion (GO:0007155) 
NRXN1 neurexin 1 -1.68 2p16.3 55(AutDB), 
Voineagu et al. 
(2011) 
Regulation of neurotransmitter levels 
(GO:0001505) 
Cell adhesion (GO:0007155) 
Synaptic transmission (GO:0007268) 
Synaptogenesis (GO:0007416) 
Biological adhesion (GO:0022610) 
KCND2 Potassium voltage-gated channel, 
Shal-related subfamily, member 
2 
-1.67 7q31 3(AutDB) Ion transport (GO:0006811) 
SEMA5A sema domain, seven 
thrombospondin repeats (type 1 
and type 1-like), transmembrane 
domain (TM) and short 
cytoplasmic domain, 
(semaphorin) 5A 
-1.66 5p15.2 11(AutDB), 
Voineagu et al. 
(2011) 
Cell motion (GO:0006928) 
Axonogenesis (GO:0007409) 
Neuron differentiation (GO:0030182) 
Tube development (GO:0035295) 
KLF7 Kruppel-like factor 7 
(ubiquitous) 
-1.66 2q32 Nishimura et al. 
(2007) 
Transcription (GO:0006350) 
 Cell motion (GO:0006928) 
Axonogenesis (GO:0007409) 
Dendrite development (GO:0016358) 
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Neuron differentiation (GO:0030182) 
SCN1a sodium channel, voltage-gated, 
type I, alpha subunit 
-1.61 2q24.3 19(AutDB) Regulation of action potential (GO:0001508) 
Ion transport (GO:0006811) 
Locomotory behavior (GO:0007626) 
AQP4 aquaporin 4 -1.60 18q11.
2-
q12.1 
Gregg et al. 
(2008) 
Water transport (GO:0006833) 
EXOC6B Exocyst complex component 6B -1.52 2p13.3
-p13.2 
2(AutDB) Exocytosis (GO:0006887) 
A2BP1 ataxin 2 binding protein 1 -1.51 16p13.
3 
Garbett et al. 
(2008) 
RNA processing (GO:0006396) 
RBM8A RNA binding motif protein 8A 1.50 1q12 2(AutDB) mRNA processing (GO:0006397) 
ARIH1 ariadne ubiquitin-conjugating 
enzyme E2 binding protein 
homolog 1 (Drosophila) 
1.53 15q24 Voineagu et al. 
(2011) 
Proteolysis (GO:0006508) 
TFAM transcription factor A, 
mitochondrial 
1.54 10q21 Gregg et al. 
(2008) 
Transcription (GO:0006350) 
TUBB6 tubulin, beta 6 1.59 18p11.
21 
Chen et al. 
(2015) 
Microtubule-based process (GO:0007017) 
(B) COX-2-/- E16 
MEF2C myocyte enhancer factor 2C -2.96 5q14 14(AutDB), Hu 
et al. (2009) 
Vasculature development (GO:0001944) 
Transcription (GO:0006350) 
Apoptosis (GO:0006915) 
GRM5 Glutamate receptor, metabotropic 
5 
-2.83 11q14.
2-
q14.3 
3(AutDB), 
(Voineagu et 
al., 2011) 
Behavior (GO:0007610) 
Learning or memory (GO:0007611) 
Regulation of synaptic plasticity (GO:0048167) 
BACH1 BTB and CNC homology 1 -2.59 21q22.
11 
Hu et al. (2009) Transcription (GO:0006350) 
KLF7 Kruppel-like factor 7 
(ubiquitous) 
-2.18 2q32 Nishimura et al. 
(2007) 
Transcription (GO:0006350) 
Cell motion (GO:0006928) 
Axonogenesis (GO:0007409) 
Dendrite development (GO:0016358) 
Neuron differentiation (GO:0030182) 
FCER1G Fc receptor, IgE, high affinity I, 
gamma polypeptide 
-2.10 1q23 Ghahramani 
Seno et al. 
(2011) 
Regulation of cytokine production (GO:0001817) 
Chemotaxis (GO:0006935) 
Immune response (GO:0006955) 
Behavior (GO:0007610) 
Regulation of apoptosis (GO:0042981) 
TSC2 tuberous sclerosis 2 -2.07 16p13.
3 
16(AutDB) Neural tube formation (GO:0001841) 
Chemotaxis (GO:0006935) 
Cell projection organization (GO:0030030) 
SRPR signal recognition particle 
receptor ('docking protein') 
-2.00 11q24.
3 
Nishimura et al. 
(2007) 
Protein localization (GO:0008104) 
NRXN1 neurexin 1 -1.98 2p16.3 55(AutDB), 
Voineagu et al. 
(2011) 
Regulation of neurotransmitter levels 
(GO:0001505) 
Cell adhesion (GO:0007155) 
Synaptic transmission (GO:0007268) 
Synaptogenesis (GO:0007416) 
Biological adhesion (GO:0022610) 
PCDHA7 Protocadherin alpha 7 -1.92 5q31 3(AutDB) Cell adhesion (GO:0007155) 
RAI1 retinoic acid induced 1 -1.88 17p11.
2 
8(AutDB), 
Voineagu et al. 
(2011) 
Skeletal system development (GO:0001501) 
Regulation of growth (GO:0040008) 
Regulation of transcription (GO:0045449) 
B3GALT6 similar to UDP-Gal:betaGal beta 
1,3-galactosyltransferase, 
polypeptide 6; UDP-Gal:betaGal 
beta 1,3-galactosyltransferase, 
polypeptide 6 
-1.88 1p36.3
3 
Voineagu et al. 
(2011) 
Polysaccharide biosynthetic process (GO:0000271) 
Glycosylation (GO:0070085) 
MDGA2 MAM domain containing 
glycosylphosphatidylinositol 
anchor 2 
-1.87 14q21.
3 
5(AutDB), 
Voineagu et al. 
(2011) 
Spinal cord development (GO:0021510) 
Neuron differentiation (GO:0030182) 
SOX5 SRY (sex determining region Y)-
box 5 
-1.81 12p12.
1 
3(AutDB) Transcription (GO:0006350) 
Regulation of neurogenesis (GO:0050767) 
TNIK TRAF2 and NCK interacting 
kinase 
-1.81 3q26.2
-
q26.31 
Ghahramani 
Seno et al. 
(2011) 
Phosphorylation (GO:0016310) 
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TRIO TrioÃ‚Â Rho guanine nucleotide 
exchange factorÃ‚Â  
-1.77 5p15.2 5(AutDB), Hu 
et al. (2009) 
Phosphorylation (Rho/Ras) (GO:0016310) 
SCN1a sodium channel, voltage-gated, 
type I, alpha subunit 
-1.74 2q24.3 19(AutDB) Regulation of action potential (GO:0001508) 
Ion transport (GO:0006811) 
Locomotory behavior (GO:0007626) 
GPD2 Glycerol-3-phosphate 
dehydrogenase 2 (mitochondrial) 
-1.73 2q24.1 3(AutDB) Glucose metabolic process (GO:0006006) 
GSK3B Glycogen synthase kinase 3 beta -1.72 3q13.3 2(AutDB) Re-entry into mitotic cell cycle (GO:0000320) 
Wnt receptor signaling pathway (GO:0016055) 
KCND2 Potassium voltage-gated channel, 
Shal-related subfamily, member 
2 
-1.71 7q31 3(AutDB) Ion transport (GO:0006811) 
KIF1B kinesin family member 1B -1.70 1p36.2 Garbett et al. 
(2008) 
Synaptic transmission (GO:0007268) 
Neuromuscular synaptic transmission 
(GO:0007274) 
Anterograde axon cargo transport (GO:0008089) 
CDH8 cadherin 8, type 2 -1.69 16q22.
1 
7(AutDB) Cell adhesion (GO:0007155) 
A2BP1 ataxin 2 binding protein 1 -1.69 16p13.
3 
Voineagu et al. 
(2011) 
RNA processing (GO:0006396) 
SETBP1 SET binding protein 1 -1.64 18q21.
1 
4(AutDB)   
GRIP1 glutamate receptor interacting 
protein 1 
-1.64 12q14.
3 
9(AutDB) Protein localization (GO:0008104) 
RNF182 ring finger protein 182 -1.63 6p23 Voineagu et al. 
(2011) 
Proteolysis (GO:0006508) 
SPAG9 sperm associated antigen 9 -1.57 17q21.
33 
Nishimura et al. 
(2007) 
Activation of MAPK activity (GO:0000187) 
Phosphorylation (GO:0016310) 
CDC42B
PB 
CDC42 binding protein kinase 
beta (DMPK-like)Ã‚Â  
-1.54 14q32.
3 
2(AutDB) Cytoskeleton organization (GO:0007010) 
Phosphorylation (GO:0016310) 
MYT1L Myelin transcription factor 1-like -1.53 2p25.3 8(AutDB) Transcription (GO:0006350) 
ZMYND1
1 
Zinc finger, MYND-type 
containing 11 
-1.52 10p14 3(AutDB) Transcription (GO:0006350) 
RBM8A RNA binding motif protein 8A 1.50 1q12 2(AutDB) mRNA processing (GO:0006397) 
PRPF40a PRP40 pre-mRNA processing 
factor 40 homolog A (yeast) 
1.54 2q23.3 Hu et al. (2009) mRNA metabolic process (GO:0016071) 
RSAD2 radical S-adenosyl methionine 
domain containing 2 
1.55 2p25.2 Ghahramani 
Seno et al. 
(2011) 
Immune response (GO:0006955) 
TMED2 transmembrane emp24 domain 
trafficking protein 2; predicted 
gene 10698; predicted gene 7318 
1.58 12q24.
31 
Gregg et al. 
(2008) 
Vesicle-mediated transport (GO:0016192) 
TM9SF2 Transmembrane 9 Superfamily 
Member 2  
1.61 13q32.
3 
Hu et al. (2009)   
TUBB6 tubulin, beta 6 1.71 18p11.
21 
Garbett et al. 
(2008) 
Microtubule-based process (GO:0007017) 
RPA3 predicted gene 6195; replication 
protein A3 
1.78 7p22 Hu et al. (2009) DNA replication (GO:0006260) 
GLO1 glyoxalase I 2.01 6p21.3
-p21.1 
9(AutDB) Anti-apoptosis (GO:0006916) 
(C) COX-1-/- E19 
MYT1L Myelin transcription factor 1-like -4.05 2p25.3 8(AutDB) Transcription (GO:0006350) 
B3GALT6 similar to UDP-Gal:betaGal beta 
1,3-galactosyltransferase, 
polypeptide 6; UDP-Gal:betaGal 
beta 1,3-galactosyltransferase, 
polypeptide 6 
-2.85 1p36.3
3 
Voineagu et al. 
(2011) 
Polysaccharide biosynthetic process (GO:0000271) 
Glycosylation (GO:0070085) 
APOE apolipoprotein E -1.88 19q13.
2,19q1
3.32 
Hu et al. (2006) Vasculature development (GO:0001944) 
Steroid catabolic process (GO:0006706) 
Cellular ion homeostasis (GO:0006873) 
Cholesterol homeostasis (GO:0042632) 
Regulation of apoptosis (GO:0042981) 
SEMA5A sema domain, seven 
thrombospondin repeats (type 1 
and type 1-like), transmembrane 
domain (TM) and short 
-1.60 5p15.2 11(AutDB) Cell motion (GO:0006928) 
Axonogenesis (GO:0007409) 
Neuron differentiation (GO:0030182) 
Tube development (GO:0035295) 
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cytoplasmic domain, 
(semaphorin) 5A 
CAMK4 Calcium/calmodulin-dependent 
protein kinase IV 
-1.56 5q21.3 1(AutDB) Synaptic transmission (GO:0007268) 
Phosphorylation (GO:0016310) 
Neurological system process (GO:0050877) 
Nuclear transport (GO:0051169) 
NRXN3 neurexin 3 1.76 14q31 9(AutDB) Regulation of neurotransmitter levels 
(GO:0001505) 
Synaptic transmission (GO:0007268) 
Synaptogenesis (GO:0007416) 
NRXN2 neurexin 2 1.79 11q13 3(AutDB) Regulation of neurotransmitter levels 
(GO:0001505) 
Synaptic transmission (GO:0007268) 
Synaptogenesis (GO:0007416) 
(D) COX2 -/- E19 
FCER1G Fc receptor, IgE, high affinity I, 
gamma polypeptide 
-3.12 1q23 Ghahramani 
Seno et al. 
(2011) 
Regulation of cytokine production (GO:0001817) 
Chemotaxis (GO:0006935) 
Immune response (GO:0006955) 
Behavior (GO:0007610) 
Regulation of apoptosis (GO:0042981) 
B3GALT6 similar to UDP-Gal:betaGal beta 
1,3-galactosyltransferase, 
polypeptide 6; UDP-Gal:betaGal 
beta 1,3-galactosyltransferase, 
polypeptide 6 
-2.19 1p36.3
3 
Voineagu et al. 
(2011) 
Polysaccharide biosynthetic process (GO:0000271) 
Glycosylation (GO:0070085) 
TSC2 tuberous sclerosis 2 -1.83 16p13.
3 
16(AutDB) Neural tube formation (GO:0001841) 
Chemotaxis (GO:0006935) 
Cell projection organization (GO:0030030) 
UAP1 UDP-N-acetylglucosamine 
pyrophosphorylase 1 
-1.80 1q23.3 Hu et al. (2006)   
SRPR signal recognition particle 
receptor ('docking protein') 
-1.76 11q24.
3 
Nishimura et al. 
(2007) 
Protein localization (GO:0008104) 
BDH1 3-hydroxybutyrate 
dehydrogenase, type 1 
-1.57 3q29 Garbett et al. 
(2008) 
Oxidation reduction (GO:0055114) 
CDKN1B Cyclin-dependent kinase 
inhibitor 1B (p27, Kip1) 
-1.55 12p13.
1-p12 
1(AutDB) Regulation of cyclin-dependent protein kinase 
activity (GO:0000079) 
Ion transport (GO:0006811) 
Cell cycle (GO:0007049) 
Neurological system process (GO:0050877) 
Cognition (GO:0050890) 
SEMA5A sema domain, seven 
thrombospondin repeats (type 1 
and type 1-like), transmembrane 
domain (TM) and short 
cytoplasmic domain, 
(semaphorin) 5A 
-1.55 5p15.2 11(AutDB) Cell motion (GO:0006928) 
Axonogenesis (GO:0007409) 
Neuron differentiation (GO:0030182) 
Tube development (GO:0035295) 
SORL1 similar to sortilin-related 
receptor, LDLR class A repeats-
containing; sortilin-related 
receptor, LDLR class A repeats-
containing 
1.55 11q23.
2-
q24.2 
Hu et al. (2009) Lipid transport (GO:0006869) 
GLO1 glyoxalase I 1.90 6p21.3
-p21.1 
9(AutDB) Anti-apoptosis (GO:0006916) 
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3.1.4. Cross-talk between COX-PGE2 and Wnt signalling pathways 
Previous in vitro research in our lab has shown the presence of a cross-talk between 
COX/PGE2 and the canonical Wnt pathway (Wong et al., 2014, Wong et al., 2016). Our most 
recent study of mice exposed to PGE2 during early prenatal development has also shown this 
interaction existing in the developing brain (Rai-Bhogal, 2016). In this study, we found 8 
differentially expressed genes that belong to the Wnt pathways exclusively in the COX-2-/- 
mouse model at E16 (Table 3B). Interestingly, these differentially expressed genes belong to the 
canonical Wnt pathway, planer cell polarity (PCP) and Wnt/Ca2+ pathways (Figure 5; indicated 
in blue). The three up-regulated genes included secreted frizzled-related protein 1 and 2 (SFRP1 
and 2), and Dishevelled Associated Activator of Morphogenesis 1 (DAAM1). While casein kinase 
1 epsilon (CK1ɛ), glycogen synthase kinase-3 beta (GSK3β), cyclin D2 (CCND2), β-actin 
(ACTβ), and protein phosphatase 3 catalytic subunit alpha (PPP3CA; CaN) were down-
regulated. These genes encode for proteins that play an important role in Wnt signal transduction. 
CK1ɛ and GSK-3β are involved in the activation of β-catenin in the canonical Wnt pathway; 
CCND2, is encoded by a target gene of the canonical Wnt pathway; DAAM1 is a key component 
of the PCP pathway; and SFRP1 and 2 are extracellular modulators if Wnt signalling. PPP3CA is 
one of the three isozymes of calcineurin A which forms calcineurin (CaN) heterodimers that are 
subunits of the calmodulin binding catalytic subunit belonging to the Wnt/Ca2+ pathway. 
Interestingly, we also found down-regulation of the gene encoding for β-actin (ACTβ), belonging 
to the focal adhesion pathway (Figure 5). AutDB and human GWAS studies were used to 
determined ASD genes belonging to the Wnt pathways. These ASD genes include Wnt1, Wnt2, 
GSK-3β, β-catenin, APC, Prickle 1/2, an isoform of TCF, and an isoform of PLC (Figure 5; 
indicated in red). Overall, these findings indicate that defects in COX-2/PGE2 signalling can 
affect the expression of many Wnt target genes critical for early brain development. 
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Figure 5: The interaction between Wnt and PGE2 pathways with genes found in the COX-
2-/- mice at E16. Affected genes found in COX-2-/- E16 are indicated in blue and genes 
associated with ASD (AutDB) are depicted in red. Here we show that the canonical, PCP and 
Wnt/Ca2+ pathway are affected due to COX-2 ablation. GSK-3β which is a crucial element of the 
canonical pathway has been affected in both the knockouts and implicated in ASD. Expression 
of some Wnt-target genes in the canonical pathway, including Ptgs2 from Wong et al., 2014 is 
also shown. This figure was recreated from the KEGG Wnt Signalling Pathway 
(http://www.genome.jp/kegg-bin/show_pathway?hsa04310). 
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3.1.6. Validation of gene expression 
To validate the microarray findings, we quantified expression of MYT1L, GLO1 and 
DAAM1 using qRT-PCR. We chose MYT1L and GLO1 as they are both ASD risk genes and are 
highly differentially regulated in the microarray, while DAAM1 is an important gene involved in 
Wnt pathways (Basu et al., 2009). qRT-PCR showed a similar pattern of down-regulated FC of 
the MYT1L gene as in the microarray analysis (Supplementary Table S1), in the COX-2-/- E16 (-
1.40±0.04, P = 0.011) and COX-1-/- E19 (-1.66±0.01, P = 0.0004) knockouts. qRT-PCR also 
confirmed up-regulated expression of GLO1 in both E16 and 19 stages of COX-2-/- with FCs of 
2.28±0.05 (P = 0.0009) and 1.95±0.02 (P = 0.0001), respectively. Lastly, we also found an 
elevated expression pattern of DAAM1 in the COX-1-/-  E19 (1.23±0.21, P = 0.193) knockout, 
although not significantly different, and validated expression in the COX-2-/- E19 (1.67±0.19, P 
= 0.037) knockout. Overall, all knockout models, except COX-1-/- E16 which is to be further 
tested, were found to indicate qRT-PCR expression levels confirming the reliability of the 
microarray results. 
3.1.5. Differential regulation of active forms of β-catenin in COX-/- mice 
 We have previously identified in vitro PGE2 dependent activation of β-catenin, a major 
downstream regulator of the canonical Wnt pathway, in NE-4C stem cells (Wong et al., 2014). 
Along with the finding of differentially expressed Wnt genes, β-catenin was found to be 
activated in the brains of offspring maternally exposed to PGE2 during prenatal development 
(Rai-Bhogal, 2016). These findings have clearly outlined a cross talk between the Wnt and PGE2 
pathways. To further investigate the cross-talk between COX-PGE2 and the canonical Wnt 
pathway in the COX-/- mice, we determined the relative levels of two active forms of β-catenin 
using western blot analysis. β-catenin can be regulated with a complex set of post-translational 
modifications by several proteins. Phosphorylation of β-catenin at S552 by PKA results in 
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stabilization, activation, nuclear localization and Wnt pathway and target gene transcription 
(Taurin et al., 2006, Taurin et al., 2008). Furthermore, phosphorylation at Ser33, Ser37 and 
Thr41 (S33/S37/T41) by GSK-3β results in destabilization and degradation (Liu et al., 2002, 
Kimelman and Xu, 2006), thus we quantified both phospho (S552) and non-phospho 
(S33/S37/T41) forms of active β-catenin.  
Among COX-/- mice of the E16 stage, we found a significant increase in FC of phospho 
β-catenin (S552) in the COX-2-/- mouse model. More specifically, while COX-1-/- did not show 
any change, we found phospho β-catenin (S552) to be up-regulated by a factor of 4.49±0.13 (P = 
0.0015) in the COX-2-/- mouse model compared to WT mice (Figure 6A). In contrast, non-
phospho β-catenin levels were unchanged compared to WT for both COX-/- models at the E16 
stage (Figure 6B). In the E19 stage, phospho β-catenin (S552) levels were unchanged in the 
COX-1-/- model, while a significant decrease in the COX-2-/- mouse model was observed with a 
FC of 0.52±0.071 (P = 0.022) (Figure 7A). Non-phospho β-catenin levels in the E19 stage 
indicated a significant increase in the COX-1-/- mice with FC of 2.05±0.14 (P = 0.017), while 
COX-2-/- indicated no change compared to WT (Figure 7B). These results indicate an altered 
level of PKA dependent phospho β-catenin (S552) in the brain of COX-2-/- mice. More 
specifically, in the COX-2-/- mice, phospho β-catenin levels were sharply elevated during E16 
and decreased during E19, compared to the respective WT stages of development. These 
findings further add to our previous in vitro and in vivo studies involving PGE2 exposure which 
have shown an interaction between COX-PGE2 and the canonical Wnt pathway (Wong et al., 
2014, Rai-Bhogal, 2016). In the COX knockout models, we have shown that the interaction is 
apparent in COX-2-/- mice at the E16 stage.  
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Figure 6: Levels of phospho β-catenin (S552) and non-phospho β-catenin (S33/S37/T41) in 
both COX-1-/- and 2-/- mice models, compared to WT, at the E16 stage. A marked increase in 
PKA dependent phospho β-catenin (S552) by the FC of 4.49±0.13 (P = 0.0015) in the COX-2-/- 
mice was observed (A). While there was no change in non-phospho β-catenin. Data shown as 
mean±SEM of 3 independent experiments (N = 3) with statistical significance represented by *P 
< 0.05 and **P < 0.01.  
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Figure 7: Levels of phospho β-catenin (S552) and non-phospho β-catenin (S33/S37/T41), in 
both COX-1-/- and 2-/- mice models, compared to WT, during E19. While there was no 
significant change for COX-1-/-; a reduced level of phospho β-catenin (S552) by FC of 
0.52±0.071 (P = 0.022) was observed for the COX-2-/- mice (A). Non-phospho β-catenin level 
was altered in the COX-1-/- mice with FC of 2.05±0.14 (P = 0.017), with no change observed for 
COX-2-/- (B). Data shown as mean±SEM of 3 independent experiments (N = 3) with statistical 
significance represented by *P < 0.05 and **P < 0.01. 
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3.2. Study 2 
3.2.1. Gene expression in undifferentiated NE-4C stem cells 
 Although transcription of genes during development is tissue and cell specific, we aimed 
to examine the expression level of selected genes from our microarray study, in our 
neuroectodermal NE-4C stem cell models treated with PGE2. We carried out qRT-PCR in our 
undifferentiated and differentiated NE-4C cell model treated with 1 µM PGE2. The genes we 
selected have been outlined above and were chosen due to their association with ASD, and thus 
their importance for neuronal development, or their involvement in the Wnt pathway. The genes 
quantified for this study included: NRXN1, NRXN3, GLO1, GRM5, DAAM1 and SOX11. In the 
NE-4C stem cell model treated with PGE2 these genes were also differentially regulated. We 
found that NRXN1, NRXN3, GLO1 and GRM5 were all down-regulated compared to untreated 
cells with RQ values 0.63±0.10 (P = 0.035), 0.57±0.07 (P = 0.013), 0.70±0.08 (P = 0.037) and 
0.38±0.17 (P = 0.033), respectively (Figure 8). DAAM1 and SOX11 expression was lower but not 
statistically different from the untreated NE-4C stem cells. The results presented have been 
normalized to the geometric mean of the housekeeping genes HPRT and PGK1 which were not 
changed with PGE2 treatment (Figure 8). Thus, the changes in expression of selected genes was 
due to the PGE2 treatment. Although the regulation of gene expression may be tissue and cell 
specific, these results indicate that an increased level of PGE2 in our in vitro model can also 
result in differential expression of genes that we found to be altered in the COX-/- microarray 
study. These results provide further evidence for COX/PGE2 signalling modulating the 
expression of important neurodevelopmental genes in undifferentiated NE-4C stem cells. 
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Figure 8: Differential gene expression in untreated and 1 µM PGE2 treated NE-4C stem 
cells. A statistically significant down-regulation was observed for NRXN1, NRXN3, GLO1 and 
GRM5 with RQs of 0.63±0.10 (P = 0.035), 0.57±0.07 (P = 0.013), 0.70±0.08 (P = 0.037) and 
0.38±0.17 (P = 0.033), respectively. Daam1 and Sox11 along with housekeeping controls, HPRT 
and PGK1, were not significantly different. Data shown as mean±SEM of 3 independent 
experiments (N = 3) with statistical significance represented by *P < 0.05 and **P < 0.01. 
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3.2.2. Gene expression in neuronally differentiated NE-4C stem cells 
We also wanted to determine whether PGE2 influences expression level of selected genes 
(as described in the previous section) in neuronally differentiated NE-4C stem cells. 
Differentiation of NE-4C stem cells has been carried out previously in our lab (Wong et al., 
2016). The cells were treated with PGE2 at the onset of differentiation (see methods) and on Day 
8 the cells were confirmed to be fully differentiated into neurons in both treated and untreated 
conditions (Wong et al., 2016). In this study, as with the undifferentiated NE-4C cells, we 
studied NRXN1, NRXN3, GLO1, GRM5, DAAM1 and SOX11. From these, we found statistically 
significant changes in expression level of NRXN1 and GLO1 in the neuronal cells treated with 
PGE2 (Figure 9). In contrast to undifferentiated stem cells, NRXN1 and GLO1 were both up-
regulated with an RQ of 1.27±0.03 (P = 0.0063) and 1.23±0.04 (P = 0.016), respectively. Along 
with the remaining genes, the housekeeping genes were stable between the treated and untreated 
neuronal cells (Figure 9). Since the housekeeping genes were not significantly different between 
treatments, the results were taken to be reliable. Taken together, these results further indicate that 
PGE2 signalling can modulate gene expression of important developmental genes in neuronal 
cells, providing implications for the developing brain. 
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Figure 9: Gene expression in neuronally differentiated NE-4C stem cells. NRXN1 indicated a 
significant 1.27±0.03 fold increase (P = 0.0063) compared to untreated neuronal cells. Similarly, 
GLO1 expression was also higher with 1.23±0.04 (P = 0.016) increase in neuronal cells 
compared to untreated neuronal cells. NRXN3, GRM5, DAAM1 and SOX11 indicated no change 
between untreated and treated neuronal cells. Housekeeping genes indicated no change. Data 
shown as mean±SEM of 3 independent experiments (N = 3) with statistical significance 
represented by *P < 0.05 and **P < 0.01. 
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4.0. DISCUSSION 
4.1. Study 1 
 Mounting evidence suggests that lipid signalling is an important component of brain 
development and pathogenesis of ASDs (Tamiji and Crawford, 2010b, Ning et al., 2015, Wong 
et al., 2015). Environmentally or genetically induced abnormalities in the activity of PGE2, 
which is the most abundant prostanoid in the brain, have been implicated in ASD. Levels of 
essential FAs and lipid mediators have consistently been found to be increased or decreased in 
the blood plasma of children with ASD, which can potentially resulting in abnormal levels of 
PGE2 (Tamiji and Crawford, 2010b, El-Ansary and Al-Ayadhi, 2012, Brigandi et al., 2015). 
Prenatal exposure to misoprostol, a PGE2 analogue, has been found to result in symptoms of 
ASD in children (Bandim et al., 2003). Furthermore, polymorphisms in the PTGS2 gene, which 
encodes for COX-2, have been enriched in children with ASDs (Yoo et al., 2008). While COX 
enzymes have distinct roles in the brain, both are responsible for the production of PGE2 and 
both may play an important role in brain development. In addition to reduced levels of FAs in the 
plasma of children with ASD, common over the counter NSAIDs also act by inhibiting COX 
enzymes, thus it is important to understand cellular events that may arise from reduced COX 
activity (Silberstein and Stirpe, 2014). Here, we used COX-/- mice offspring as an experimental 
model of down-regulated PGE2 and ASD to characterize the effects of abnormal PGE2 signalling 
on gene expression during critical periods of prenatal brain development (Ayoub et al., 2004, 
Bosetti et al., 2004).  
In this study, we examined global gene expression during prenatal days E16 and 19 in 
male mouse models lacking either COX-1 or COX-2 enzymes. Since abnormalities in the COX-
PGE2 signalling pathway have been associated with ASD, we hypothesized that many essential 
ASD associated developmental genes would be dysregulated in the brain of animals lacking 
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COX enzymes. We found that COX enzyme ablation at the earlier stage of E16 during which 
neurogenesis occurs has a greater impact on gene expression than the later stage (E19). This was 
demonstrated not only by the greater number of genes differentially expressed in the E16 mice 
compared to E19, but also by the greater portion of genes down-regulated in the E16 mice. 
Furthermore, COX-2 disruption resulted in a greater impact on gene expression compared to 
COX-1, especially for E16. Thus, this impact during E16 in the COX-2-/- mice also resulted in a 
greater number of biological pathways and ASD risk genes found. Interestingly, we have also 
shown the existence of a cross talk between the PGE2 and Wnt pathways via activation of β-
catenin exclusively in the COX-2-/- mouse model during E16. Taken together, these findings 
suggest that E16 spans a more critical period for disruption of normal COX-PGE2 function than 
E19 and COX-2-/- plays a more important developmental role than COX-1-/-. There are several 
reasons for why the distinction between the COX enzymes exists.  
Although PGE2 is the major prostanoid synthesized in the brain, due to marked functional 
and cellular differences between the two COX isozymes, the differences we have observed in our 
knockout mice are not surprising. Among many distinguishing characteristics of the COX 
enzymes, inducibility has been well described; with COX-1 being primarily constituent in 
microglia and vascular cells (Hoozemans et al., 2001, Amateau and McCarthy, 2004, Garcia-
Bueno et al., 2009, Kirkby et al., 2012). Conversely, COX-2 is inducible except in neuronal cells, 
with subcellular localization in synapses of key brain regions, including cerebral cortex, 
hippocampus and amygdala, especially during early development (Vane et al., 1998, Maslinska 
et al., 1999, Wang et al., 2005, Hewett et al., 2006, Aid and Bosetti, 2011). In addition, Vazquez-
Tello et al. (2004) have found enzymes important for downstream PGE2 synthesis subcellularly 
colocalize with COX-1 in microsomal vesicles or COX-2 in both microsomal and 
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nuclear/perinuclear fractions of brain cells. Thus, it is possible that COX-1 may provide PGE2 
for local paracrine signalling, while COX-2 may produce PGE2 for intracellular regulation of 
gene expression through EP receptors present on intracellular membranes (Vazquez-Tello et al., 
2004, Zhu et al., 2006). These localization studies and their implications for the distinct roles of 
the two COX enzymes may explain why we found a greater impact on gene expression in the 
COX-2-/- mouse model compared to COX-1-/-. Furthermore, the constitutive expression of COX-
2-/- in neuronal cells exclusively suggests that the changes we found in the COX-2-/- mice are due 
to gene expression changes in developing neurons and not microglia. In addition, the differences 
in localization and our results also suggest that the COX enzymes are not redundant in their 
function and that knockout of only one COX enzyme and not both is still a relevant model to 
study. However, despite these major differences, we did find some functional overlap between 
the two COX enzymes.  
The dysfunction of gene expression and pathways found in both COX-/- mouse models 
indicate the importance of both COX enzymes during prenatal development. Our Venn diagram 
analysis indicating many genes in common between the COX-/- mouse models during E16 and 
E19. Specifically, the pathways involved in synaptic development were found to be effected in 
both knockouts of the E16 developmental stage. Taken together, these results have shown that 
both COX/PGE2 signalling pathways are capable of regulating genes that carry out the same 
biological function during brain development. This is especially true for the more critical day of 
E16 with 10 pathways in common, while E19 indicated 3 pathways in common.  
4.1.1. Syndromic ASD genes 
Many of the genes and pathways found in this study are important for neuronal 
development and implicated in ASD pathogenesis. Of interest were MYT1L, in both COX-1-/- 
mice; and TSC2, in both COX-2-/- mice (Basu et al., 2009). These genes were considerably 
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down-regulated in their respective model systems. MYT1L is a protein predominantly expressed 
in neurons and homologous to MYT1 which is an important TF for the regulation of myelin 
formation (Kim and Hudson, 1992). Mutations in this gene have been implicated in mental 
retardation, schizophrenia and ASD-like behaviour (Gruchy et al., 2007, Bonaglia et al., 2009, 
Meyer et al., 2012). Mutation of TSC2 and 1 result in Tuberous Sclerosis Complex (TSC) which 
is a severe disorder involving intellectual disability, seizures, disorder in multiple organs, 
including benign tumours in the brain, and ASD like behaviour (Davis et al., 2015). The 
prevalence of ASD in TSC cases ranges from 26-50% (Jeste et al., 2008, Leclezio and de Vries, 
2015). Interestingly, the TSC proteins are important components of the mechanistic target of 
rapamycin (mTOR) signalling pathway which regulates synaptic plasticity and memory as it 
responds to the signals coming from neuronal surface receptors (Lasarge and Danzer, 2014). 
Thus, ASDs in individuals with TSC involves neuronal specific and synaptic associated 
pathways found in our analysis of the COX-/- knockout mice transcriptome. Indeed, several 
studies, involving similar functional analyses of human or rodent ASD associated samples or 
gene lists, have indicated pathways found in our knockout models (Anney et al., 2011, Kumar et 
al., 2011, Sgado et al., 2013, An et al., 2014, Cristino et al., 2014, Ning et al., 2015). Here, we 
will discuss current research and implications of synaptic development and transmission along 
with Wnt pathways enriched in our analysis, which involved many other ASD associated genes 
of interest. 
4.1.2. Synaptic development and transmission 
Abnormal neuronal transmission found in both COX-/- mouse models at E16 has also 
been characterized in ASDs as abnormal synaptic transmission is considered a hallmark of ASD 
neuro-pathophysiology (Bourgeron, 2009, Ebert and Greenberg, 2013, Sala et al., 2015, Lin et al., 
2016, Liu et al., 2016). While we found both COX enzymes to alter synaptic transmission during 
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the E16 stage they are both distinct in the way they can alter synaptic development and 
transmission (Chen et al., 2002, Yoo et al., 2008). COX-1 is constitutively expressed in 
microglial cells in the brain, these cells are highly involved in the early synaptic development 
and pruning, as well as synaptic function (Hoozemans et al., 2001, Roumier et al., 2004, 
Roumier et al., 2008, Paolicelli et al., 2011, Schafer et al., 2013). Furthermore, in adult mouse 
models, research indicating PGE2 resulting from COX-1, not COX-2, with induced hippocampal 
inflammation is responsible for contextual memory impairment, a process which requires normal 
synaptic transmission (Matousek et al., 2010). In contrast, COX-2 is constitutively expressed in 
excitatory neuronal cells of the brain and localized in the post-synaptic buds of dendrites and 
developing dendritic spines (Kaufmann et al., 1996). With direct experimental techniques, COX-
2 has consistently been found to play an important role in synaptic transmission and plasticity, 
predominantly through the production of PGE2 (Chen et al., 2002, Chen and Bazan, 2005, Sang 
and Chen, 2006). Synaptic transmission is thought to be important for postnatal life when 
sensory stimulation and learning begins, however synaptic activity in the prenatal brain also 
occurs and is considered crucial for the formation of neuronal connections for proper 
development (Moody and Bosma, 2005, Moore et al., 2011). Taken together, both COX enzymes 
play crucial roles in synaptic transmission and, here, we have provided further evidence in the 
prenatal mouse brain lacking either COX enzyme. It is important to outline the pathways we 
found in our microarray analysis and their implications for neuronal development and ASD 
pathogenesis. 
In the E16 stage of development, several important regulatory mechanisms were enriched, 
including long-term potentiation (KEGG:mmu04720), in the COX-1-/- model; and long-term 
depression (KEGG:mmu04730) and axon guidance (KEGG:mmu04360) in the COX-2-/- model. 
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Additionally, regulation of nerve impulse (GO:0019226) and synaptic transmission 
(GO:0050804) were enriched in both E16 COX-/- models. While we have shown cell culture 
neurite retraction induced by PGE2 treatment in previous findings, this study indicates an in vivo 
link between COX-2 mediated PGE2 and axon guidance (Tamiji and Crawford, 2010b). Several 
synaptic genes differentially expressed in the E16 knockouts have been implicated in ASDs, 
including GRM5, calcium/calmodulin dependent protein kinase IV (CAMK4), glycogen synthase 
kinase 3 beta (GSK3B), sodium voltage-gated channel alpha subunit 1 (SCN1A), kinesin family 
member 1B (KIF1B), and neurexin 1 (NRXN1). In the pre-birth stage of E19, regulation of nerve 
impulse (GO:0019226) and secretion (GO:0046903) pathways were enriched in COX-1-/- mice 
with ASD-risk genes including CAMK4, neurexin 2 (NRXN2) and neurexin 3 (NRXN3) 
differentially expressed. The enrichment of pathways relating to synaptic development and 
function, and corresponding genes, indicates the significant role of COX enzymes during brain 
development. Next, we will outline some of the important genes outlined here. 
GRM5, encoding for metabotropic glutamate receptor 5 (mGluR5), was considerably 
down-regulated in our E16 knockout mice and is of particular importance as it is not only crucial 
for brain development but also strongly associated with ASD pathophysiology (Reichelt et al., 
2012, Zantomio et al., 2015). Interestingly, in a computer model that uses genomic SNP data to 
predict whether a child has ASD, GRM5 was one of the three genes that were the most critical 
for the accurate prediction of a positive ASD diagnosis later in life (Skafidas et al., 2014). GRM5 
expression levels and mGluR5 positive neurons have been shown to be lower in the prefrontal 
cortex of individuals with ASDs (Chana et al., 2015). Furthermore, microglial density was 
significantly increased in GRM5-/- mice compared to controls (Chana et al., 2015). Functional 
variants of the GRM5 gene have also been found to be enriched in 290 non-syndromic ASD 
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cases compared to 300 controls (Kelleher et al., 2012). It is important to note that while 
neurotransmission does not directly involve metabotropic receptors, such as mGluR5, they are 
integral for regulating and modulating neurotransmission (Wijetunge et al., 2008, She et al., 2009, 
Loerwald et al., 2015). A microarray study of post-mortem ASD cerebellum particularly found 
abnormal glutamate neurotransmission (Purcell et al., 2001). The normal development of 
functional neurons and the inhibitory/excitatory balance requires a crucial group of proteins, 
belonging to the NRXN-NLGN-SHANK pathway, which have consistently been implicated in 
ASD pathophysiology and have been implicated in our COX-/- study (Autism Genome Project et 
al., 2007, Dalva et al., 2007, Durand et al., 2007, Peca et al., 2011, Yang et al., 2012). 
Several genes that have been differentially expressed in our COX-/- mice models belong 
to the NRXN-NLGN-SHANK pathway which is very important for synaptic development and 
function. NRXN1, which was highly down-regulated in our E16 mouse models, and other 
synaptic specific CAMs differentially expressed in our microarray have been implicated in ASD 
pathogenesis (Zoghbi, 2003, Garber, 2007). While NRXN2 and 3 have some associations with 
ASD pathogenesis, significant and mounting evidence has strongly implicated NRXN1 as an 
ASD susceptibility gene (Autism Genome Project et al., 2007, Gauthier et al., 2011, Reichelt et 
al., 2012, Vaags et al., 2012, Bena et al., 2013, Chen et al., 2014b). Deletions in the NRXN1 gene 
have resulted in syndromic ASD cases displaying intellectual disability, severe language delay 
and seizures (Bena et al., 2013). Additional CAMs found in our knockouts include CDH8, 
PCDHA7 and contactin 2 (CNTN2). CNTN2 was differentially expressed in both COX knockout 
models of both stages of development, but it has not particularly been identified as an ASD 
candidate gene. However, CNTN2 interacts with CNTNAP2, which is a strong ASD candidate 
protein of the NRXN family (Arking et al., 2008, Bakkaloglu et al., 2008). Thus, abnormal 
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expression of the CNTN2 gene may alter the function of CNTNAP2, resulting in abnormal 
neuronal development. Taken together, these differentially expressed genes code for proteins that 
are key for the NRXN-NLGN-SHANK pathway and proper synaptic development. Thus, these 
results provide further evidence supporting the function of COX-PGE2 in the regulation of 
synaptic development and function, which is vital for early brain development and a hallmark of 
ASD pathogenesis (Chaudhury et al., 2016). 
4.1.3. COX-PGE2 and Wnt signalling 
One of the more interesting findings in our microarray data is the enrichment the Wnt 
signalling pathway in the COX-2-/- knockout at the E16 stage. The interaction between 
COX/PGE2 signalling and Wnt signalling has been characterized in vitro in non-neuronal cells 
(Yoshida et al., 2013, Li et al., 2014, Hiyama et al., 2015), and in vivo studies of zebrafish 
(Goessling et al., 2009, North et al., 2010). Interestingly, a PGE2 dose dependent effect on Wnt 
signalling has also been described in osteoblast-lineage cells, with a high and low dose reducing 
and increasing Wnt transcription, respectively (Liu et al., 2010). Furthermore, our lab was the 
first to demonstrated the cross-talk between the PGE2 and Wnt signalling pathways within the 
context of neuronal development in NE-4C neuronal stem cells and the developing mouse brain 
(Wong et al., 2014, Rai-Bhogal, 2016, Wong et al., 2016). This interaction has primarily been 
found to occur through the activity of PKA and PI-3K which are the main downstream kinases of 
PGE2 signalling (Sheng et al., 2001, Fujino et al., 2002, Castellone et al., 2005). Using PKA and 
PI-3K inhibitors we have shown that greater attenuation of Wnt induced changes in cell 
behaviour result from PKA inhibition than PI-3K inhibition (Wong et al., 2014). Thus, PKA has 
a greater role in PGE2 induced Wnt modulation than PI-3K in NE-4C cells (Wong et al., 2014). 
Interestingly, our previous in vivo study indicated an elevated level of phospho β-catenin (S552) 
in the E16 brain of mice prenatally exposed to PGE2 (Rai-Bhogal, 2016). The evidence of PGE2 
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modulating the Wnt pathway emphasizes the importance of maintaining normal lipid 
biochemistry during prenatal and early life. 
The significance of finding the Wnt pathway enriched in our COX-2-/- mouse model 
during the E16 stage of prenatal development is highlighted by the importance of the Wnt 
pathway during development. The Wnt signalling pathway is responsible for global 
developmental patterning, particularly anterior-posterior patterning of the embryo (Arkell et al., 
2013) and neural tube formaton (Ciani and Salinas, 2005, Ille and Sommer, 2005). The Wnt 
pathway also regulates cell fate determination, cell proliferation, neuronal migration, 
differentiation, axon development, dendritic spine development and synaptic development 
(Wassink et al., 2001, Rosso et al., 2005, Chen et al., 2006, Marui et al., 2010, Kalkman, 2012, 
Zhang et al., 2014). Interestingly, along with the Wnt signalling it self, neural migration, axon 
guidance and synaptic function have not only been effected in our COX knockout models, but 
also in individuals with ASD (Watts, 2008, Okerlund and Cheyette, 2011, Zhang et al., 2014). In 
this study, differentially expressed genes belonging to the Wnt pathway have provided further 
evidence for the interaction between COX-PGE2 and Wnt signalling pathways.  
Our previous findings mentioned above show that PGE2 signalling can interfere 
specifically with the Wnt canonical pathway. The current study revealed for the first time that 
PGE2 signalling can affect all three Wnt pathways. Altered function of Wnt signalling was 
revealed in the COX-2-/- model at the E16 developmental stage through the dysregulation of 8 
genes that belong to either the canonical, PCP or Wnt/Ca2+ pathways (Figure 5). The genes 
casein kinase 1 epsilon (CK1ɛ), glycogen synthase kinase-3 beta (GSK3β) and cyclin D2 
(CCND2) belong to the canonical pathway; dishevelled-associated activator of morphogenesis 1 
(DAAM1) and β-actin (ACTβ) belong to the PCP pathway; protein phosphatase 3 catalytic 
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subunit alpha (PPP3CA; CaN) belongs to the noncanonical Wnt/Ca2+ pathway; and secreted 
frizzled-related protein 1 (SFRP1), secreted frizzled-related protein 2 (SFRP2) act as 
extracellular modulators of Wnt activity. GSK-3β, a key component of the destruction complex, 
was not only up-regulation in our COX-2-/- E16 mouse model but is also an ASD risk gene. 
Cyclin D2 is crucial for neuron proliferation and neurogenesis as shown by the ablation of adult 
neurogenesis in a CCND2 knockout mouse model (Jedynak et al., 2014). Furthermore, 
macrocephaly, a well known characteristic of early ASD symptomology, and other severe 
abnormalities have been observed in children born with de novo CCND2 mutations (Klein et al., 
2013, Mirzaa et al., 2014). SFRP1 and 2 transcripts were found to be up-regulated, these proteins 
act as endogenous inhibitors of FZD receptors (Chung et al., 2009). While higher PGE2 levels 
have been shown to modulate canonical Wnt activity as shown in our previous studies (Wong et 
al., 2014, Wong et al., 2016), here we have also shown that complete knockout of the PGE2 
producing enzyme COX-2 can result in abnormal regulation of genes that belong to all three Wnt 
pathways.  
4.1.4. Altered β-catenin activation in COX-/- mice 
To further assess whether the PGE2 and Wnt pathways interact in our COX
-/- mouse 
models, we determined relative levels of active β-catenin, the major downstream signalling 
molecule in the canonical Wnt pathway. β-catenin is normally subjected to PTMs that stabilizing 
or destabilizing its function. These PTMs can depend on the “on” or “off” state of canonical Wnt 
signalling or by kinases that can phosphorylate β-catenin. These kinases, acting independently of 
the destruction complex, include PKA, which phosphorylates S552 and S675; and protein kinase 
B (PKB, also known as AKT), which also phosphorylates S552 (Taurin et al., 2006, Fang et al., 
2007). Phosphorylation of S675 has been shown to result in β-catenin binding to C-AMP 
response element-binding protein (CREB)-binding protein, which results in transcription (Taurin 
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et al., 2006). However, phosphorylation at S552 results in β-catenin nuclear translocation and 
TCF/LEF transcriptional activity as part of the canonical Wnt pathway (Fang et al., 2007, Taurin 
et al., 2008, Zhao et al., 2010). Phosphorylation at S552 by PKB also results in β-catenin induced 
transcriptional activity (Fang et al., 2007). PKB is primarily involved in growth factor receptor 
signalling, such as epidermal and insulin-like growth factors which regulate growth and glucose 
metabolism (Fang et al., 2007, Chen et al., 2014a). Interestingly, in addition to direct S552 
phosphorylation and activation of β-catenin, insulin receptor signalling can activate PKB via PI-
3K which inhibits GSK-3β, resulting in the stabilization of β-catenin and TCF/LEF 
transcriptional activity (Cross et al., 1995, Weston and Davis, 2001, Fang et al., 2007). This may 
also occur with PGE2 signalling as PI-3K, along with PKA, is also activated downstream of the 
PGE2 pathway. Thus, while PKA may directly activate β-catenin, PI-3K can indirectly ensure β-
catenin stability by inhibiting the destruction complex via PKB inhibiting GSK-3β.  
We have found that while both PKA and PI-3K play a role in Wnt modulation in our in 
vitro NE-4C stem cells, PKA plays a greater role in Wnt modulation (Wong et al., 2014). This 
may ensure that, if S552 phosphorylation does not protect β-catenin from degradation (this is 
likely the case), the inhibition of the destruction complex would prevent degradation. We have 
recently found altered levels of S552 phosphorylation in the brain of mice prenatally exposed to 
PGE2 (Rai-Bhogal, 2016). In our current findings, a marked increase in phosphorylation of S552 
suggests greater PKA activity in the E16 prenatal brain of male COX-2-/- mice. This increase was 
followed by a decrease in S552 β-catenin in the E19 COX-2-/- mouse model. The transient 
increase in β-catenin S552 phosphorylation at E16 followed by a seemingly over compensated 
decrease at E19 in the COX-2-/- may partly account for differential expression of Wnt pathway 
associated genes and Wnt target genes in the COX-2-/- mouse model. Similar to our previous 
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findings of PGE2 altering Wnt activity in NE-4C cells (Wong et al., 2014, Wong et al., 2016), the 
in vivo COX-2-/- deficient mouse model indicates an increase of active β-catenin. These results 
collectively indicate that an increase or decrease of PGE2 during development may alter 
canonical Wnt activity. Overall, these results provide further evidence for the developmental role 
of PGE2 via modulation of the canonical Wnt pathway. The effect of PGE2 signalling on the PCP 
or Wnt/Ca2+ pathways has not been documented and still needs to be investigated further. 
In this study, we also found the relative quantity of stable non-phosphorylated β-catenin 
which arises when a Wnt ligand inhibits the destruction complex. In the absence of a Wnt signal, 
CK1 of the destruction complex primes β-catenin, by phosphorylating S45 (Amit et al., 2002, 
Liu et al., 2002, Yanagawa et al., 2002), this, in turn, allows GSK-3β to phosphorylate the 
residues S33/S37/T41 leading to ubiquitination and proteasomal degradation of β-catenin (Liu et 
al., 2002, Kimelman and Xu, 2006). Conversely, a canonical Wnt ligand can activate specific 
FZD receptors, leading to inhibition of the destruction complex. This allows stable β-catenin to 
remain non-phosphorylated at S33/S37/T41, this results in accumulation and translocation to the 
nucleus, allowing for the activation of gene transcription (Okerlund and Cheyette, 2011). Thus, 
the relative quantity of non-phospho β-catenin (S33/S37/T41) found in this study not only 
indicates the amount of stabilized β-catenin but also transcriptionally active β-catenin present, 
similar to phospho β-catenin (S552). This form of β-catenin was not altered in either COX-/- 
model during the E16 stage of development. However, at the later stage in the COX-1-/- model, 
there is an increase of non-phospho β-catenin (S33/S37/T41) level, suggesting that the 
destruction complex is inhibited at E19. The aforementioned inhibitory mechanisms that can act 
on the destruction complex involve Dvl, after Wnt ligand induced FZD activation; and PI-
3K/PKB, from insulin and possibly PGE2 signalling pathways. Evidently, neither of these are 
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very active in the earlier stage of development and only seem to be active in COX-1-/- E19 mouse 
models. Overall this data suggests that in the COX-2-/- mouse model, Wnt is modulated by 
mechanisms independent of the destruction complex and instead through kinases which can 
activate β-catenin.  
4.1.5. Limitations and future studies 
Growing evidence shows that COX-PGE2 is a candidate pathway involved in the 
pathology of ASD. In this study, we identified many differentially expressed genes implicated in 
ASD in prenatal COX knockout mice brains; indicating that COX-/- mice may serve as model 
systems for studying ASDs. However, one of the limitations of this study was the use of COX 
knockout mice with a background of two mixed strains, one of those strains (C57BL/6) served as 
the WT mice in this study; this could have introduced genetic confounds between the 
experimental and control results. In addition, this study was limited to male offspring, thus, a 
similar microarray analysis in female offspring will be carried out to determine sex specific 
implications of COX enzymes in ASD pathogenesis. To further identify the link between COX 
enzyme knockout and ASD, we are carrying out ASD behavioural studies in male and female 
COX knockout model as well as mice treated with PGE2 prenatally. Overall, these results 
provide several interesting aspects that may be explored further using a variety of experiments 
and model systems. 
4.1.6. Conclusion  
ASDs are a set of neurodevelopmental disorders which are becoming increasingly more 
prevalent. These disorders are enigmatic in the sense that much is known about contributing 
pathophysiological characteristics and yet categorical or preventable etiologies are not concretely 
understood. Due to this limited understanding of ASDs, functional annotation tools allow for the 
grouping of genes by function to make more applicable conclusions about ASDs. Furthermore, 
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most ASD risk genes have been identified using genomics in rare and syndromic ASD cases 
while other more common ASD cases remain idiopathic. This suggests it is important to use 
unconventional techniques such as analysis of the transcriptome, proteome and epigenetics. 
These techniques can help reveal functional changes that can result from the interaction between 
environmental factors, such as inflammation and dietary imbalances early in life, and differential 
gene expression. Thus, while genomic studies have revealed much and are very important, 
transcriptomic studies should also be carried out, particularly in idiopathic ASD cases. We have 
taken these factors in consideration by carrying out functional analysis and determining 
transcriptional changes in the prenatal brains of mice lacking COX enzymes. With this, we have 
not only shown that COX enzymes, especially COX-2, are important for brain development but 
also strongly implicated in ASD pathogenesis and etiology. While the central role of COX/PGE2 
in inflammatory response has consistently been associated with ASD, we have provided further 
evidence for its role in axon development, synaptic transmission and Wnt signalling pathways 
(COX-2 only) which are also implicated in ASDs. These results suggest that the COX-2-/- mouse 
model may be considered a potential mouse model for studying ASDs.  
 
4.2. Study 2 
4.2.1. Differential gene expression of key synaptic and developmental genes in differentiated 
and undifferentiated NE-4C stem cells 
 To further demonstrate whether abnormal PGE2 signalling affects gene expression during 
neuronal development, we quantified gene expression of important genes from our microarray in 
NE-4C stem cells, an in vitro model for embryonic neuronal stem cells, treated with PGE2. We 
found that NRXN1, NRXN3, GLO1 and GRM5, all of which were also affected with PGE2 
treatment. Consistent evidence implicating NRXNs, particularly NRXN1 (Autism Genome 
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Project et al., 2007, Gauthier et al., 2011, Reichelt et al., 2012, Vaags et al., 2012, Bena et al., 
2013, Chen et al., 2014b); and mGluR5 (Kelleher et al., 2012, Skafidas et al., 2014, Chana et al., 
2015) in ASD pathogenesis already exist and the current study provides further evidence for the 
important role of PGE2 signalling in the brain. 
GLO1 is a ubiquitously expressed cytosolic zinc metalloenzyme responsible for the 
removal of glycotoxins, primarily methylglyoxal (MG) which is a product of glycolysis and 
other reactions in the cell (Thornalley, 2008, Roy et al., 2016). GLO1 is a rate limiting enzyme 
required for the removal of MG from the cytosol and ultimately leading to the formation of lactic 
acid and glutathione which are non-toxic and used for additional biochemical reactions (Junaid et 
al., 2004, Maher, 2012). Proteomic study of autopsied ASD brain samples indicated abnormal 
polarity and reduced function of GLO1 and with sequencing revealed SNPs in the GLO1 gene 
significantly enriched in an ASD cohort (Junaid et al., 2004). Reduced function of GLO1 results 
in increased levels of MG which can react with other molecules in the cell to form advanced 
glycation end-products (AGEs) (Junaid et al., 2004, Maher, 2012). Both MG and AGEs 
contribute to oxidative stress, inflammation, mitochondrial dysfunction, age related neurological 
diseases and, more recently, ASDs (Thornalley, 2008, Maher, 2012). MG and AGEs can be 
found in common high heat treated foods such as deep-fried potatoes and fried meat (Tan et al., 
2008, Birlouez-Aragon et al., 2010, Semba et al., 2010). Dietary MG and AGEs have been linked 
to oxidative stress and inflammation due to up-take from gut into the blood (Vlassara et al., 2002, 
Cai et al., 2008, Vlassara and Striker, 2011). Furthermore, these toxins can also be maternally 
transmitted to the fetus which may contribute to ASD pathogenesis (Mericq et al., 2010). 
Although more causal and direct studies are needed, these toxins appear to be a potential source 
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of stress during development arising from maternal transmission or reduced GLO1 expression 
caused by mutations or abnormal PGE2 signalling.  
4.2.2. Differential gene expression in neuronally differentiated NE-4C stem cells 
 We have previously shown that PGE2 accelerates the neuronal-lineage differentiation 
process in NE-4C stem cells (Wong et al., 2016). More specifically, PGE2 results in the earlier 
formation of neuronal clusters or neurospheres along with earlier expression of neuronal markers. 
In addition, PGE2 exposure leads to altered Wnt regulated genes previously implicated in 
neurodevelopmental disorders, and increased levels of active β-catenin (Wong et al., 2016). To 
further elucidate the way in which PGE2 may alter gene expression, we quantified the transcripts 
of NRXN1, NRXN3, GLO1, GRM5, DAAM1 and SOX11 genes of interest from the microarray in 
neuronally differentiated cells. Both NRXN1 and GLO1 were significantly up-regulated, while 
the remaining genes were unaffected. The importance of these genes has been discussed above 
and their differential expression in neuronal cells further provide evidence that PGE2 can 
regulate important genes in neuronal cells as well. Overall, these results add to the mounting 
evidence indicating that PGE2 has a role in brain development and is associated with ASD 
pathogenesis. 
4.2.3. Limitations and future studies 
 Although we have found significant changes in gene expression in both NE-4C stem cells 
and differentiated neuronal cells, these studies should be followed up with protein analysis to 
indicate translational changes in these genes. Furthermore, with several altered genes being 
important for synaptic neurobiology, cell based electrophysiological recordings can also be 
considered. 
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4.2.4. Conclusion 
 The in vitro studies carried out here have added evidence supporting what we have 
consistently shown in our lab; the important role of PGE2 in early brain development. Previous 
cell behavioural studies with abnormal PGE2 signalling, we have indicated altered division, 
migration, calcium homeostasis, extension growth and differentiation in in vitro cell models. 
Here we have provided additional candidate genes that may contribute to the previously 
observed cell behavioural changes caused by altered PGE2 signalling. Overall, PGE2 signalling 
pathway is important for normal neuronal stem cell and neuron cells, dysregulation of which 
may contribute to changes resulting in ASD pathogenesis.  
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5.0. CONCLUSION 
The studies conducted here have provided a comprehensive outline of the role of COX 
enzymes and PGE2 in prenatal mouse models of neuronal development. To our knowledge, we 
have conducted the first global gene expression analysis of male mouse brains lacking either 
COX-1 or COX-2 enzymes at two prenatal time periods. Additional evidence implicating PGE2 
signalling for altering expression of important genes in neuroectodermal stem cells and 
differentiated neurons was also provided. Examining expression during two different time 
periods was integral for demonstrating the importance of critical periods during prenatal brain 
development and we have shown that E16 falls in a more critical period for lipid signalling in the 
brain than E19. In addition, transcriptomic studies have been proven to be a valuable tool for 
identification of functional changes that may be associated with ASDs. The microarray analysis 
provided further evidence for COX/PGE2 regulating synaptic neurobiology and Wnt signalling 
pathways (COX-2 only) which are vital for brain development and strongly implicated in ASDs. 
Taken together, we have provided sufficient evidence for the potential use of COX knockout 
models, especially COX-2-/-, as viable ASD mouse models for further studies.  
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7.0. APPENDIX 
A.1. Supplementary Figure 
Table S1: FC of all genes differentially expressed in COX-1-/- E16, COX-2-/- E16, COX-1-/- 
E19, and COX-2-/- E19. Only the genes with absolute FC > 1.5 and statistically significant (P-
value < 0.05) genes were included in our bioinformatics analysis. We found a total of 229, 323, 
134 and 148 differentially expressed genes in COX-1-/- E16, COX-2-/- E16, COX-1-/- E19 and 
COX-2-/- E19 mouse models, respectively. 
COX-1-/- E16 COX-2-/- E16 COX-1-/- E19 COX-2-/- E19 
Official Gene 
Symbol 
FC Official Gene 
Symbol 
FC Official Gene 
Symbol 
FC Official Gene 
Symbol 
FC 
Hbb-y 4.34 Hbb-b2 10.88 Hbb-b2 11.15 Hbb-b2 12.83 
SOX11 3.39 Hbb-y 5.15 C030014C12Rik 3.91 Paip1 3.74 
slc35f1 2.09 Xlr4a 3.99 SOX11 3.17 PBX1 3.68 
Lyplal1 2.03 SOX11 3.30 LOC100045240 2.89 Ankrd37 3.01 
TMEM87A 2.02 Paip1 3.21 Ankrd37 2.75 SOX11 2.73 
RBM45 2.01 0710001D07Rik 2.42 CAP1 2.66 Sfrp1 2.59 
sdcbp 1.97 ABCC10 2.36 Paip1 2.58 GLTPD1 2.49 
LOC100044314 1.92 emp1 2.34 GLTPD1 2.46 trim2 2.25 
0710001D07Rik 1.89 LUM 2.32 Prkd3 2.45 Serpina3n 2.22 
DCN 1.89 trim2 2.22 Egr1 2.42 DAAM1 2.12 
Rnase4 1.88 LOC100044314 2.17 TMEM87A 2.35 C030014C12Rik 2.10 
Hba-x 1.88 Lyplal1 2.09 LOC100044314 2.18 0710001D07Rik 2.08 
Snapc3 1.86 COL3A1 2.05 trim2 2.13 LOC100044314 1.98 
CAP1 1.86 slc35f1 2.01 FOS 2.13 ENSMUSG000000
68790 
1.93 
Paip1 1.85 GLO1 2.01 Fezf1 2.11 4930455C21Rik 1.92 
NFIB 1.84 gjb2 2.00 RBM45 1.97 GLO1 1.90 
ITGB3BP 1.84 GLTPD1 1.96 Sfrp1 1.96 NEK3 1.89 
LUM 1.82 DCN 1.96 Lyplal1 1.96 Lyplal1 1.87 
DTD1 1.81 Hba-x 1.91 C530036F05Rik 1.88 Prkd3 1.83 
IL18 1.79 sdcbp 1.88 GRLF1 1.84 WARS2 1.82 
2810417H13Rik 1.76 Slc13a4 1.88 TXNIP 1.83 Ttc15 1.81 
SCP2 1.76 Sfrp1 1.84 6330415B21Rik 1.82 GRLF1 1.80 
ABCC10 1.74 IL22RA1 1.83 DAAM1 1.81 ADI1 1.78 
ADI1 1.74 GNG10 1.79 mro 1.80 4833414E09Rik 1.77 
LOC100045240 1.72 2810417H13Rik 1.79 2900011L18Rik 1.80 pitx2 1.74 
vps33a 1.68 Hexb 1.79 NRXN2 1.79 LOC100046025 1.72 
nosip 1.68 NUBP2 1.79 pitx2 1.78 LOC100045240 1.72 
Rpa3 1.65 Rpa3 1.78 Ttc15 1.78 lhx1 1.69 
Hbb-bh1 1.65 NDUFB10 1.78 Nrxn3 1.76 SSBP4 1.68 
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Hyexb 1.65 HEBP1 1.76 2310016E02Rik 1.76 LYPD1 1.68 
CUEDC1 1.64 PFDN4 1.76 ADI1 1.73 cdkal1 1.67 
emp1 1.63 MRPL47 1.75 GPM6B 1.71 Arcn1 1.67 
ZBTB8OS 1.63 TMEM47 1.74 3830612M24 1.69 ahnak 1.65 
itgb1bp1 1.62 Col6a3 1.74 0710001D07Rik 1.69 2310016E02Rik 1.65 
SSBP4 1.62 Gpx8 1.73 ITGB3BP 1.69 UNC80 1.62 
fign 1.62 Arcn1 1.73 FANK1 1.69 GNB4 1.61 
LYPD1 1.61 Clcn4-2 1.71 Klf4 1.68 Psg23 1.61 
Asnsd1 1.61 TUBB6 1.71 LYPD1 1.68 ATP10D 1.61 
LOC280487 1.61 sfrp2 1.70 Nnat 1.67 Gins4 1.61 
Clcn4-2 1.61 LOC100046025 1.69 9930031P18Rik 1.63 TMEM66 1.61 
GTF3C2 1.60 TSPAN12 1.68 SCP2 1.62 pdia6 1.60 
Col5a2 1.60 OGN 1.68 Hexb 1.61 C530036F05Rik 1.60 
PFDN4 1.60 2310016E02Rik 1.67 SSBP4 1.61 MPP7 1.60 
Ttc15 1.59 SEPP1 1.67 Hist1h1c 1.59 COL3A1 1.59 
TUBB6 1.59 ADI1 1.66 Nkx6-2 1.59 ST18 1.59 
AURKAIP1 1.58 SSBP4 1.66 nkx2-1 1.58 gjb2 1.58 
Col6a3 1.57 CETN2 1.66 ST18 1.57 emp1 1.57 
TRAPPC2 1.57 Col5a2 1.65 ZWINT 1.56 NUBP2 1.57 
SH3BGRL 1.57 DAAM1 1.64 Uevld 1.54 myo6 1.56 
Egr1 1.55 mgst1 1.64 Phkb 1.54 GMCL1 1.56 
TSPAN12 1.55 ahnak 1.64 ZFYVE27 1.54 SORL1 1.55 
Gpx8 1.55 2410076I21Rik 1.63 ZBTB33 1.54 FANK1 1.55 
Prpf40a 1.54 Asnsd1 1.63 CEBPB 1.53 2900011L18Rik 1.55 
TFAM 1.54 E130114P18Rik 1.62 ANGPT2 1.53 CHCHD8 1.55 
2310016E02Rik 1.54 p2ry12 1.62 vps33a 1.53 Zfp286 1.54 
E130114P18Rik 1.54 MLF1 1.62 NEK3 1.52 Hexb 1.54 
HIF1A 1.54 ST18 1.61 Ppp1ca 1.51 esd 1.52 
GNG10 1.54 COMMD1 1.61 Col5a2 1.51 Phkb 1.52 
mrps10 1.53 Jam3 1.61 Arcn1 1.50 Col6a3 1.50 
ARIH1 1.53 Tm9sf2 1.61 UNC80 1.50 EPM2AIP1 -10.02 
GMPS 1.52 pdia6 1.61 Cox7a2l -8.06 TMEM25 -7.27 
STAG2 1.52 DTD1 1.60 Zfp68 -5.73 NDUFB10 -6.53 
spc25 1.51 KPNA2 1.60 MCM6 -5.68 Cops8 -5.01 
RECK 1.51 ppiC 1.60 SPARC -5.35 UBE2I -4.98 
RBM8A 1.50 NFIB 1.60 ACTL6B -5.29 Gpr137b-ps -4.92 
2810008M24Rik 1.50 EBF3 1.59 Cops8 -5.22 TM7SF3 -4.84 
SPARC -8.05 TRAPPC2 1.58 MYT1L -4.05 Rn18s -4.52 
Zfp68 -6.10 Tmed2 1.58 Rn18s -3.90 rpl29 -4.44 
ACTL6B -5.79 GMPS 1.58 Hbb-b1 -3.89 wdr82 -3.76 
MYT1L -5.48 DLK1 1.58 TM7SF3 -3.68 EMB -3.74 
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Cops8 -5.34 FKBP7 1.58 ACTB -3.12 SPARC -3.32 
CCNG2 -5.32 TPBG 1.57 Akr1c19 -2.91 Slc25a18 -3.19 
TM7SF3 -4.27 spc25 1.57 B3galt6 -2.85 FCER1G -3.12 
Bach2 -4.20 Zfp606 1.57 arl5a -2.78 MCM6 -3.05 
MCM6 -4.15 ENSMUSG000000
68790 
1.57 Gpr137b-ps -2.64 FGFR1OP2 -2.69 
cxadr -4.14 Ttc15 1.57 PUSL1 -2.59 Mboat2 -2.66 
PRKAG2 -3.97 fundc1 1.56 Mboat2 -2.55 Hbb-b1 -2.51 
Cox7a2l -3.84 fign 1.56 2900003A17Rik -2.48 2900003A17Rik -2.44 
ACTB -3.51 calml4 1.56 CAPN2 -2.36 mgst1 -2.44 
ARV1 -3.31 SH3BGRL 1.56 twistnb -2.19 CAPN2 -2.40 
Akr1c19 -3.16 RSAD2 1.55 SFRS16 -2.18 C030014I23Rik -2.37 
Mtap2 -3.15 USP14 1.55 PKIG -2.15 arrdc3 -2.32 
Mboat2 -3.03 ESCO2 1.55 homer2 -2.13 SFRS16 -2.31 
2900003A17Rik -3.01 LOC280487 1.55 hpcal1 -2.09 SV2A -2.27 
twistnb -2.99 Tspan6 1.55 CNTN2 -2.09 6330418B08Rik -2.25 
arl5a -2.95 ccng1 1.55 DHRSX -2.09 Nudt6 -2.25 
MEF2C -2.85 tpmT 1.55 FGFR1OP2 -2.04 TAGAP -2.23 
Grm5 -2.81 UBE2N 1.55 PKM2 -2.02 Defb11 -2.20 
TAF6 -2.80 cdkal1 1.54 Cd200 -2.02 ATP8A1 -2.20 
Hbb-b1 -2.78 HIST1H2BK 1.54 melA -2.01 B3galt6 -2.19 
Man2b1 -2.75 HIF1A 1.54 TAF6 -2.00 NT5C3 -2.14 
Zmiz1 -2.75 tmod3 1.54 6330418B08Rik -1.99 melA -2.11 
CNTN2 -2.74 KCNN1 1.54 ALG9 -1.97 Stk25 -2.10 
B3galt6 -2.70 Tgfbr2 1.54 Stk25 -1.96 PUSL1 -2.10 
melA -2.63 HNRNPA2B1 1.54 Trappc5 -1.94 4833420G17Rik -2.06 
PCDH17 -2.63 Phkb 1.54 GIN1 -1.90 CNTN2 -2.04 
Dpysl3 -2.58 RPGR 1.54 RpL30 -1.89 AI316807 -1.99 
FGFR1OP2 -2.58 Zfp286 1.54 APOE -1.88 GIN1 -1.98 
ALG9 -2.57 Pcp4l1 1.54 AGPAT5 -1.87 ppp1r14c -1.96 
PKM2 -2.57 Prpf40a 1.54 Tia1 -1.87 PHTF1 -1.91 
AGPAT5 -2.54 LYPD1 1.54 Znhit1 -1.86 rps3a -1.91 
1500035N22Rik -2.53 THBD 1.53 MRPS27 -1.85 Cox7a2l -1.90 
ZDHHC21 -2.52 Rrm1 1.53 Rec8 -1.84 ahcY -1.90 
PCDH7 -2.43 3830406C13Rik 1.53 STXBP2 -1.83 D830030K20Rik -1.88 
Rn18s -2.40 1810035L17Rik 1.53 TAGAP -1.81 CCRN4L -1.88 
DENND1C -2.36 UBE2A 1.52 lancl1 -1.81 Map4k5 -1.87 
GRIA2 -2.36 STAG2 1.51 TMEM25 -1.78 Lars2 -1.86 
hpcal1 -2.35 frmd3 1.51 Defb11 -1.78 TSC2 -1.83 
PRDX2 -2.34 FOXC2 1.51 Mrpl55 -1.76 rps2 -1.82 
BRD2 -2.28 GTF3C2 1.51 ahcY -1.75 UAP1 -1.80 
4833414E09Rik -2.27 srp9 1.51 pts -1.72 Tmed4 -1.80 
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Bach1 -2.24 Hbb-bh1 1.51 ZBTB45 -1.71 EME2 -1.78 
THAP4 -2.24 2610036L11Rik 1.50 THAP4 -1.70 STXBP2 -1.78 
NECAB1 -2.15 RBM8A 1.50 LASS4 -1.68 Ipo9 -1.77 
Rec8 -2.09 3110052M02Rik 1.50 Fbxo46 -1.67 SRPR -1.76 
SLC4A4 -2.05 EPM2AIP1 -7.39 iars2 -1.62 Mrpl55 -1.76 
DHRSX -2.02 UBE2I -5.38 Insig2 -1.62 THAP4 -1.74 
RIOK1 -2.01 TM7SF3 -5.17 abcd3 -1.62 RpL30 -1.71 
Tia1 -2.01 Bach2 -4.99 Gpr17 -1.61 AGPAT5 -1.68 
MRPS27 -2.00 Cops8 -4.76 SEMA5A -1.60 Fbxo46 -1.67 
fam168a -2.00 SPARC -4.72 CHRNA3 -1.59 mthfd1 -1.66 
KIF1B -1.97 TMEM25 -4.69 ANAPC5 -1.59 Spsb3 -1.63 
DHCR24 -1.95 wdr82 -4.47 KCNF1 -1.58 PEX11B -1.63 
SIN3A -1.92 rpl29 -4.36 2900060N12Rik -1.57 FLYWCH2 -1.61 
PBX1 -1.91 Mtap2 -3.73 camk4 -1.56 klhl21 -1.61 
homer2 -1.91 Gpr137b-ps -3.44 9030624G23Rik -1.56 1700029J07Rik -1.60 
6330418B08Rik -1.91 GRIA2 -3.14 pygb -1.56 Cirbp -1.60 
Stk25 -1.90 Rn18s -3.12 ttc17 -1.55 ACTL6B -1.59 
Hook3 -1.90 Dpysl3 -3.12 SERINC3 -1.55 2900060N12Rik -1.57 
LOC100047888 -1.89 EMB -3.07 9930105H17Rik -1.54 BDH1 -1.57 
AHDC1 -1.89 5330423I11Rik -3.07 Gstm6 -1.53 Zfp160 -1.57 
gtpbp2 -1.86 2900003A17Rik -2.97 AI316807 -1.53 DMWD -1.56 
PKIG -1.86 MEF2C -2.96 TMEM158 -1.51 Znhit1 -1.56 
PUSL1 -1.85 Mboat2 -2.95 Phlda3 -1.51 MED23 -1.55 
Gcap14 -1.85 ODZ4 -2.90   CDKN1B -1.55 
Cd200 -1.85 Man2b1 -2.88   NLRX1 -1.55 
mmp16 -1.85 PCDH7 -2.83   H2afj -1.55 
ODZ4 -1.84 CNTN2 -2.83   SEMA5A -1.55 
D430041D05Rik -1.84 Grm5 -2.83   3110021A11Rik -1.54 
H2afj -1.82 AGPAT5 -2.77   lancl1 -1.53 
MDGA2 -1.81 FGFR1OP2 -2.76   iars2 -1.53 
PCDHA7 -1.79 CCNG2 -2.71   fut10 -1.53 
Epb4.1l2 -1.79 PRDX2 -2.68   Zfp39 -1.53 
Gpr137b-ps -1.78 Zmiz1 -2.68   DHRSX -1.52 
UBE2I -1.78 SV2A -2.65   Ccdc117 -1.51 
igsf3 -1.78 PCDH17 -2.60   OLFML3 -1.51 
AFAP1 -1.76 Bach1 -2.59   LOC674427 -1.51 
Zeb2 -1.75 ARV1 -2.51   Trappc5 -1.51 
RBBP9 -1.75 D4Ertd681e -2.50     
SYT4 -1.75 BRD2 -2.47     
palm -1.75 ZDHHC21 -2.46     
camk4 -1.75 melA -2.43     
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Fbxo41 -1.74 RIOK1 -2.38     
SERINC3 -1.73 DENND1C -2.34     
CAMKV -1.72 1200016E24Rik -2.33     
9330164J24Rik -1.72 LOC100047888 -2.32     
LOC100048372 -1.72 NECAB1 -2.32     
GLTPD1 -1.72 CSNK1E -2.27     
CDH8 -1.72 BCL11B -2.25     
Adam17 -1.71 Gcap14 -2.24     
Fbxl18 -1.71 4933407C03Rik -2.19     
ATM -1.69 POU6F1 -2.18     
C130045I22Rik -1.69 KLF7 -2.18     
NRXN1 -1.68 6330418B08Rik -2.17     
SLC4A3 -1.67 LOC100048372 -2.17     
irs2 -1.67 H2afj -2.13     
KCND2 -1.67 Stk25 -2.10     
GLG1 -1.66 FCER1G -2.10     
KLF7 -1.66 TSC2 -2.07     
SEMA5A -1.66 Ppp1r1c -2.06     
esd -1.65 ACTB -2.06     
gpsm1 -1.65 ATP8A1 -2.05     
Acsl6 -1.64 Fbxo41 -2.05     
DAG1 -1.64 Hook3 -2.04     
napB -1.64 THAP4 -2.03     
CSNK1E -1.63 9330164J24Rik -2.02     
abcd3 -1.63 SRPR -2.00     
Hps1 -1.63 TAGAP -1.99     
SERPINE2 -1.63 NRXN1 -1.98     
SNX27 -1.63 TMEM66 -1.97     
ppp3ca -1.62 ppp1r14c -1.96     
Scn1a -1.61 mmp16 -1.96     
2900060N12Rik -1.60 igsf3 -1.96     
rpe -1.60 C77370 -1.95     
H13 -1.60 PCDHA7 -1.92     
myh10 -1.60 2700089E24Rik -1.92     
Insig2 -1.60 GLG1 -1.92     
AQP4 -1.60 CASKIN1 -1.91     
ttc17 -1.60 Gnai1 -1.91     
Epb4.1l1 -1.59 6330415B21Rik -1.90     
pts -1.59 D430007A19Rik -1.90     
dnajc5 -1.58 hpcal1 -1.89     
nrp -1.58 PKM2 -1.89     
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6430548M08Rik -1.58 gtpbp2 -1.89     
Adrbk2 -1.58 Epb4.1l2 -1.89     
BCL11B -1.57 nrp -1.89     
prpf40b -1.57 B3galt6 -1.88     
camkk2 -1.57 RAI1 -1.88     
Syp -1.57 MDGA2 -1.87     
Ptprd -1.57 napB -1.86     
UBTF -1.56 Map4k5 -1.86     
CASKIN1 -1.56 SNX27 -1.84     
THY1 -1.56 Zeb2 -1.84     
Znhit1 -1.56 gpsm1 -1.83     
6430411K18Rik -1.56 irs2 -1.83     
Ppp1r1c -1.55 prpf40b -1.82     
TAGAP -1.55 Clasp1 -1.82     
SGSM1 -1.55 TNIK -1.81     
keap1 -1.55 SOX5 -1.81     
DCTN4 -1.55 keap1 -1.81     
RAPGEFL1 -1.54 SLC4A3 -1.80     
ANAPC5 -1.54 Mll1 -1.79     
mapt -1.53 TRIO -1.77     
Zfp236 -1.53 ALG9 -1.77     
ZBTB45 -1.53 Adrbk2 -1.76     
Cops5 -1.52 DAG1 -1.76     
BAI2 -1.52 CAMKV -1.76     
DGKH -1.52 C030014I23Rik -1.75     
Pbx4 -1.52 Tssc8 -1.75     
Camk2b -1.52 Scn1a -1.74     
GUCY1A3 -1.52 Gpd2 -1.73     
EXOC6B -1.52 RBM28 -1.73     
CHRNA3 -1.52 rps2 -1.73     
KCNF1 -1.51 H13 -1.73     
A2bp1 -1.51 PHTF1 -1.73     
cspg5 -1.50 SLC4A4 -1.73     
Hmg20a -1.50 GSK3B -1.72     
Ncdn -1.50 lsm12 -1.72     
GIN1 -1.50 ahcY -1.72     
  SFRS16 -1.72     
  3110021A11Rik -1.72     
  KCND2 -1.71     
  DHCR24 -1.71     
  palm -1.71     
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  4833414E09Rik -1.70     
  KIF1B -1.70     
  Rec8 -1.70     
  CDH8 -1.69     
  AFAP1 -1.69     
  dnajc5 -1.69     
  A2bp1 -1.69     
  MRPS27 -1.68     
  arrdc3 -1.68     
  MCM6 -1.67     
  D11Bwg0517e -1.67     
  Nudt6 -1.67     
  NAV1 -1.67     
  6430548M08Rik -1.67     
  E130307A14Rik -1.66     
  LOC100046343 -1.66     
  C130045I22Rik -1.66     
  AI316807 -1.65     
  ppp3ca -1.65     
  usp48 -1.65     
  2900060N12Rik -1.64     
  Ptprd -1.64     
  ZCCHC6 -1.64     
  SETBP1 -1.64     
  mapt -1.64     
  GRIP1 -1.64     
  SEZ6 -1.63     
  Epb4.1l1 -1.63     
  CLCN7 -1.63     
  AHDC1 -1.63     
  D830030K20Rik -1.63     
  RNF182 -1.63     
  them4 -1.62     
  LDB2 -1.62     
  A130054J05Rik -1.61     
  D430041D05Rik -1.61     
  Zfp131 -1.61     
  Syt1 -1.61     
  myh10 -1.59     
  EME2 -1.59     
  LOC100045679 -1.59     
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  SERPINE2 -1.58     
  Snapc3 -1.58     
  BAI2 -1.57     
  ANKMY2 -1.57     
  GIN1 -1.57     
  Fbxl18 -1.57     
  Tia1 -1.57     
  Spag9 -1.57     
  Pbx4 -1.57     
  AP1B1 -1.56     
  KLC4 -1.56     
  PUSL1 -1.56     
  Car11 -1.56     
  EXOSC10 -1.55     
  Spsb3 -1.55     
  LOC100046746 -1.55     
  Plxna2 -1.55     
  Sox6 -1.55     
  1700029J07Rik -1.55     
  Zfp281 -1.55     
  LPHN1 -1.55     
  PIP5K1A -1.54     
  ZBTB17 -1.54     
  LIMCH1 -1.54     
  vldlr -1.54     
  homer2 -1.54     
  CHD5 -1.54     
  CDC42BPB -1.54     
  GUCY1A3 -1.54     
  RAD23B -1.53     
  GABARAPL1 -1.53     
  Defb11 -1.53     
  CCND2 -1.53     
  MYT1L -1.53     
  DHRSX -1.53     
  D930015E06Rik -1.52     
  Ncdn -1.52     
  6430590A07Rik -1.52     
  zmynd11 -1.52     
  srebf2 -1.52     
  C030048H21Rik -1.52     
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  cspg5 -1.51     
  Sf1 -1.51     
  TNRC6C -1.51     
  Ngef -1.51     
  SPATA7 -1.51     
  Cfl2 -1.51     
  MED23 -1.51     
 
 
 
 
